0001161697-17-000357.txt : 20170804 0001161697-17-000357.hdr.sgml : 20170804 20170804163402 ACCESSION NUMBER: 0001161697-17-000357 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPRO MED SYSTEMS INC CENTRAL INDEX KEY: 0000704440 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133044880 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-12305 FILM NUMBER: 171009056 BUSINESS ADDRESS: STREET 1: 24 CARPENTER RD CITY: CHESTER STATE: NY ZIP: 10918 BUSINESS PHONE: 845-469-2042 MAIL ADDRESS: STREET 1: 24 CARPENTER RD CITY: CHESTER STATE: NY ZIP: 10918 10-Q 1 form_10-q.htm FORM 10-Q QUARTERLY REPORT FOR 06-30-2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to ________.

Commission File Number: 0-12305

REPRO MED SYSTEMS, INC.

(Exact name of registrant as specified in its charter)


New York	13-3044880
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

24 Carpenter Road, Chester, New York	10918
(Address of Principal Executive Offices)	(Zip Code)

(845) 469-2042

(Registrant’s telephone number, including area code)

February 28

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


	Large accelerated filer [ ]	Accelerated filer [ ]
	Non-accelerated filer [ ]	Smaller reporting company [X]
	(Do not check if a smaller reporting company)	Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

As of August 4, 2017, 37,834,871 shares of common stock, $0.01 par value per share, were outstanding, which excludes 2,737,231 shares of treasury stock.

REPRO MED SYSTEMS, INC.

TABLE OF CONTENTS


		PAGE

PART I – FINANCIAL INFORMATION

ITEM 1.	Financial Statements

	Balance Sheets as of June 30, 2017 (Unaudited) and February 28, 2017	3

	Statements of Operations (Unaudited) for the one month ended March 31, 2017 and 2016, and the three and four months ended June 30, 2017 and 2016.	4

	Statements of Cash Flows (Unaudited) for the four months ended June 30, 2017, and 2016	5

	Notes to Financial Statements	6-11

ITEM 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	12-17

ITEM 3.	Quantitative and Qualitative Disclosures About Market Risk	17

ITEM 4.	Controls and Procedures	17

PART II – OTHER INFORMATION

ITEM 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17-18

ITEM 6.	Exhibits	18

- 2 -

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

REPRO MED SYSTEMS, INC.

BALANCE SHEETS


	June 30,
	2017			February 28,
	(Unaudited)			2017
ASSETS

CURRENT ASSETS
Cash and cash equivalents	$	2,982,508		$	3,313,265
Certificates of deposit		262,315			262,314
Accounts receivable less allowance for doubtful accounts of $13,046 at June 30, 2017 and $18,046 at February 28, 2017		1,899,622			1,502,030
Inventory		1,267,214			1,353,703
Tax Receivable		—			172,457
Prepaid expenses		229,667			175,955
TOTAL CURRENT ASSETS		6,641,326			6,779,724
Property and equipment, net		901,464			932,092
Patents, net of accumulated amortization of $188,735 and $180,137 at June 30, 2017 and February 28, 2017, respectively		429,974			426,943
Other assets		31,582			31,490
TOTAL ASSETS	$	8,004,346		$	8,170,249

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Deferred capital gain - current	$	22,481		$	22,481
Accounts payable		279,130			772,428
Accrued expenses		353,997			417,357
Accrued payroll and related taxes		212,083			177,018
Accrued tax liability		1,384			—
TOTAL CURRENT LIABILITIES		869,075			1,389,284
Deferred capital gain – long term		15,002			22,496
Deferred tax liability		95,133			82,422
TOTAL LIABILITIES	$	979,210		$	1,494,202

STOCKHOLDERS’ EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 40,572,102 and 40,558,429 shares issued, 37,834,871 and 37,821,198 shares outstanding at June 30, 2017 and February 28, 2017, respectively		405,721			405,584
Additional paid-in capital		4,117,845			4,129,726
Retained earnings		2,845,774			2,484,941
		7,369,340			7,020,251
Less: Treasury stock, 2,737,231 shares at June 30, 2017 and February 28, 2017		(344,204	)		(344,204	)
TOTAL STOCKHOLDERS’ EQUITY		7,025,136			6,676,047
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	8,004,346		$	8,170,249

The accompanying notes are an integral part of these financial statements

- 3 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF OPERATIONS (UNAUDITED)


	For the One Month Ended						For the Three Months Ended						For the Four Months Ended
	March 31						June 30						June 30
	2017			2016			2017			2016			2017			2016

NET SALES	$	1,509,619		$	1,276,299		$	3,829,457		$	2,795,894		$	5,339,076		$	4,072,193
Cost of goods sold		536,823			446,618			1,532,158			1,008,749			2,068,981			1,455,367
Gross Profit		972,796			829,681			2,297,299			1,787,145			3,270,095			2,616,826

OPERATING EXPENSES
Selling, general and administrative		637,707			655,043			2,005,336			2,118,159			2,643,043			2,773,202
Research and development		7,872			14,535			24,840			57,403			32,712			71,938
Depreciation and amortization		25,576			23,536			76,781			73,041			102,357			96,577
Total Operating Expenses		671,155			693,114			2,106,957			2,248,603			2,778,112			2,941,717

Net Operating Profit/(Loss)		301,641			136,567			190,342			(461,458	)		491,983			(324,891	)

Non-Operating Income/(Expense)
Gain/(Loss) on currency exchange		19,988			36,673			34,671			(24,340	)		54,659			12,333
Interest and other income		322			321			421			752			743			1,073
TOTAL OTHER INCOME/(EXPENSE)		20,310			36,994			35,092			(23,588	)		55,402			13,406

PROFIT/(LOSS) BEFORE TAXES		321,951			173,561			225,434			(485,046	)		547,385			(311,485	)

Income Tax (Expense)Benefit		(109,590	)		(59,231	)		(76,962	)		164,834			(186,552	)		105,603

NET INCOME/(LOSS)	$	212,361		$	114,330		$	148,472		$	(320,212	)	$	360,833		$	(205,882	)

NET INCOME/(LOSS) PER SHARE

Basic	$	0.01		$	—		$	—		$	(0.01	)	$	0.01		$	(0.01	)
Diluted	$	0.01		$	—		$	—		$	(0.01	)	$	0.01		$	(0.01	)

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

Basic		37,821,198			37,966,501			37,825,209			37,964,985			37,824,189			37,965,370
Diluted		37,847,628			37,966,501			37,891,306			37,964,985			37,877,694			37,965,370

The accompanying notes are an integral part of these financial statements

- 4 -

REPRO MED SYSTEMS, INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)


	For the Four Months Ended
	June 30,
	2017			2016

CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$	360,833		$	(205,882	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Amortization of deferred compensation cost		—			7,000
Stock based compensation expense		7,615			69,714
Depreciation and amortization		102,357			96,577
Deferred capital gain - building lease		(7,493	)		(7,493	)
Deferred taxes		12,711			(15,144	)
Provision for returns and doubtful accounts		(5,000	)		(10,312	)
Changes in operating assets and liabilities:
Increase in accounts receivable		(392,592	)		(376,551	)
Decrease in inventory		86,489			1,575
Decrease/(Increase) in prepaid expense and other assets		118,652			(108,855	)
(Decrease)/Increase in accounts payable		(493,297	)		186,109
Increase/(Decrease) in accrued payroll and related taxes		35,065			(21,489	)
Decrease in accrued expense		(63,360	)		(67,383	)
Increase/(Decrease) in accrued tax liability		1,384			(92,003	)
NET CASH USED IN OPERATING ACTIVITIES		(236,636	)		(544,137	)

CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property and equipment		(63,133	)		(74,549	)
Payments for patents		(11,628	)		(29,085	)
NET CASH USED IN INVESTING ACTIVITIES		(74,761	)		(103,634	)

CASH FLOWS FROM FINANCING ACTIVITIES
Payment for cancelled shares		(19,360	)		—
Purchase of treasury stock		—			(1,105	)
NET CASH USED IN FINANCING ACTIVITIES		(19,360	)		(1,105	)

NET DECREASE IN CASH AND CASH EQUIVALENTS		(330,757	)		(648,876	)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD		3,313,265			4,201,948
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	2,982,508		$	3,553,072

Supplemental Information
Cash paid during the periods for:
Interest	$	—		$	—
Taxes	$	—		$	90,000

NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation	$	45,000		$	24,718

The accompanying notes are an integral part of these financial statements

- 5 -

REPRO MED SYSTEMS, INC.

NOTES TO THE UNAUDITED FINANCIAL STATEMENTS

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

REPRO MED SYSTEMS, INC. (the “Company”, “RMS”, or “we”) designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality management systems. The Company operates as one segment.

FISCAL YEAR END

On March 22, 2017, the Board of Directors approved a change in the Company’s fiscal year end from February 28 to December 31. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March 2017 and the quarter April through June 2017 on Form 10-Q.

BASIS OF PRESENTATION

The accompanying unaudited financial statements as of June 30, 2017, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.

In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of June 30, 2017, and the results of operations and cash flow for the four months periods ended June 30, 2017, and 2016.

The results of operations for the four months ended June 30, 2017, and 2016 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the year ended February 28, 2017, as filed with the Securities and Exchange Commission on Form 10-K.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09—Compensation-Stock Compensation (Topic 718), which provides clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this update affect any entity that changes the terms or conditions of a share-based payment award. The amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

- 6 -

In June 2016, FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.

In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The ASU clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP and International Financial Reporting Standards (“IFRS”) that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of the financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The amendments in this update are effective for the annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Full or modified retrospective adoption is required and early application is not permitted. On July 9, 2015, the FASB issued ASU No. 2015-14 Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date, which (a) delays the effective date of ASU 2014-09, Revenue from Contracts with Customers (Topic 606), by one year to annual periods beginning after December 15, 2017 and (b) allows early adoption of the ASU by all entities as of the original effective date for public entities. We currently anticipate adopting the new standard using the modified retrospective method beginning January 1, 2018. In March 2016, the FASB issued ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606); Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations and the effective date is the same as the requirements in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606); Identifying Performance Obligations and Licensing, which is intended to clarify identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas and the effective date is the same as the requirements in ASU 2014-09. In May 2016, FASB issued ASU No. 2016-12—Revenue from Contracts with Customers (Topic 606); Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by update 2014-09). In December 2016, the FASB issued ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which represents changes to make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This update is the final, combined version of Proposed Accounting Standards Updates 2016-240 and 2016-320 (both entitled Technical Corrections and Improvements), which have been deleted. Based upon our initial evaluation, we do not expect the adoption of the standard and related amendments to have a material effect on our financial condition or results of operations.

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The main difference between the current requirement under GAAP and this ASU is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases. This ASU requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Classification will be based on criteria that are largely similar to those applied in current lease accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. This is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. This ASU must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the potential impact of this ASU on our financial statements, disclosure requirements and methods of adoption.

- 7 -

The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.

STOCK-BASED COMPENSATION

The Company maintains a long-term incentive stock benefit plan under which it grants stock options and restricted stock to certain directors and key employees. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date, over the vesting period.

RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

NOTE 2 RELATED PARTY TRANSACTIONS

On December 20, 2013, we executed an agreement effective March 1, 2014, with a Company director, Dr. Mark Baker, to provide clinical research and support services related to new and enhanced applications for the FREEDOM60® Syringe Infusion System. Authorized by the Board of Directors, the agreement provides for payment of 420,000 shares of common stock valued at $0.20 per share over a three-year period. Amortization amounted to zero and $7,000 for the four months ended June 30, 2017 and 2016, respectively.

On October 21, 2015, Cyril Narishkin was appointed to the Board of Directors and Interim Chief Operating Officer of the Company. Also effective October 21, 2015, we entered into a consulting agreement with Mr. Narishkin, to support our expanded management team and accelerate our growth opportunities under his role of Interim Chief Operating Officer. The agreement provided for payment of $16,000 per month for eight days per month, of which half was to be paid in cash and half was to be paid in shares of common stock. Effective January 1, 2016, the agreement provided for the same payment of $16,000 per month, of which seventy-five percent was to be paid in cash and twenty-five percent was to be paid in shares of common stock.

On June 24, 2016, Cyril Narishkin executed a termination and general release agreement, which terminated his previous consulting agreement, and resigned as an officer and director for personal reasons. Mr. Narishkin was compensated for services as a consultant through January 31, 2017 at a monthly rate of $16,000 per month for up to eight days of service a month upon request of the Company. Mr. Narishkin’s compensation was zero and $118,000 for the four months ended June 30, 2017 and 2016, respectively. In accordance with the agreement, the Company repurchased 96,542 shares of common stock of the Company owned by Mr. Narishkin at an aggregate purchase price of $43,393.

LEASED AIRCRAFT

The Company leases an aircraft from a company controlled by Andrew Sealfon, the Company’s President and Chief Executive Officer. The lease payments were $5,668 and $7,167 for the four months ended June 30, 2017 and June 30, 2016, respectively. The original lease agreement has expired and the Company is currently on a month-to-month basis for rental payments.

BUILDING LEASE

Mr. Mark Pastreich, a director, is a principal in the entity that owns the building leased by Company. The Company is in year nineteen of a twenty-year lease. There have been no changes to lease terms since his directorship and none are expected through the life of the current lease. With a monthly lease amount of $11,042, the lease payments were $44,168 for each of the four months ended June 30, 2017 and June 30, 2016. The Company also paid property taxes for the four months ended June 30, 2017 and June 30, 2016 in the amount of $16,236 and $15,825, respectively.

We are currently seeking another location within a 30 mile radius from our current facility with more square footage to accommodate our expanding needs. In addition to the increased costs of occupying a larger space, we expect to incur additional costs in connection with construction and FDA compliance with respect to the new location. There can be no assurance that we will find a suitable location before our current lease expires on terms that are economically favorable to us or at all.

- 8 -

NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:


	June 30, 2017		February 28, 2017

Land	$	54,030	$	54,030
Building		171,094		171,094
Furniture, office equipment, and leasehold improvements		1,048,818		1,022,942
Manufacturing equipment and tooling		1,031,207		1,003,166
		2,305,149		2,251,232
Less: accumulated depreciation		1,403,685		1,319,140
Property and equipment, net	$	901,464	$	932,092

NOTE 4 LEGAL PROCEEDINGS

Lawyers representing EMED Technologies Corp. (“EMED”) sent RMS a letter dated, May 1, 2013, which alleged that the RMS High-Flo Butterfly design infringed a patent controlled by EMED. RMS disputed this claim and we believed that our design did not infringe and that the EMED patent itself was not valid. Under advice of counsel, on September 20, 2013, the Company commenced in the United States District Court for the Eastern District of California a declaratory judgment action against competitor, EMED to establish the invalidity of one of EMED’s patents and non-infringement of the Company’s needle sets. EMED answered the complaint and asserted patent infringement and unfair business practice counterclaims. The Company responded by asserting its own unfair business practice claims against EMED. Both parties have requested injunctive relief and monetary damages. Discovery is ongoing.

On June 16, 2015, the Court issued what it termed a “narrow” preliminary injunction against the Company from making certain statements regarding some of EMED’s products. On June 23, 2016, EMED filed a motion seeking to have the Company held in contempt, claiming that certain language in the Company’s device labeling does not comply with the injunction. In response to a show cause order, the Company advised the Court that the language in the Company’s labeling that EMED challenged is language that the FDA directed the Company to use in its labeling. The Court discharged the show cause order, effectively rejecting EMED’s contempt argument.

On March 24, 2016, EMED filed a motion seeking a second preliminary injunction prohibiting RMS from selling three of its products in California. The Company opposed that motion on April 19, 2016. A decision on the motion is still pending.

On June 25, 2015, EMED filed a claim of patent infringement for the second of its patents, also directed to the Company’s needle sets, in the United States District Court for the Eastern District of Texas. This second patent is related to the one concerning the Company’s declaratory judgment action. Given the close relationship between the two patents, the Company requested that the Texas suit be transferred to California. Also, based on a validity review of the patent in the U.S. Patent and Trademark Office (“USPTO”), discussed below, the Company requested the Texas suit be stayed. On May 12, 2016, the Court entered an order staying the case until after the Patent Trial and Appeal Board (“PTAB”) at the USPTO issued a final written decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its final written decision invalidating the claims asserted by EMED in the Texas litigation. On January 26, 2017, the Company and EMED requested that the Texas case remain stayed pending EMED’s appeal of the PTAB’s final ruling to the Court of Appeals for the Federal Circuit (“CAFC”).

On September 11, 2015, the Company requested an ex parte reexamination of the patent in the first filed case, and on September 17, 2015 the Company requested an inter partes review (“IPR”) of the patent in the second filed case. On November 20, 2015, the USPTO instituted the ex parte reexamination request having found a substantial new question of patentability concerning EMED’s patent in the first filed case. All EMED claims have been rejected by the USPTO Examiner in a Non-Final Office Action. EMED filed a response that is awaiting consideration by the Examiner. Thus, the ex parte reexamination is ongoing. A decision to institute the IPR for EMED’s patent in the second filed case was ordered by the USPTO on February 19, 2016 having determined a reasonable likelihood all claims of the patent may be found to be unpatentable. Oral argument for the IPR was held on November 22, 2016 and a final ruling issued on January 12, 2017. In its final ruling, the PTAB held the claim asserted by EMED against the Company in the second filed case was invalid. EMED appealed the PTAB’s final ruling, and EMED’s opening brief in the CAFC was filed on June 26, 2017. The Company is now responding.

Although the Company believes it has meritorious claims and defenses in these actions and proceedings, their outcomes cannot be predicted with any certainty. We believe that it is very likely both patents will be determined invalid, however, if any of these actions against the Company are successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

- 9 -

NOTE 5 STOCKHOLDERS’ EQUITY

On September 30, 2015, RMS’s Board of Directors authorized the Company to make open market purchases of up to 2,000,000 shares of the Company’s Outstanding Common Stock. The purchases are made through a broker designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the rules of the Securities and Exchange Commission for such repurchases. As of June 30, 2017, the Company had repurchased 396,606 shares at an average price of $0.45 under the program. The management of the Company decided to discontinue repurchasing its outstanding common stock under the program for an undetermined period of time to utilize cash for capital investments needed to expand the business.

NOTE 6 STOCK-BASED COMPENSATION

On September 30, 2015, the Board of Directors approved the 2015 Stock Option Plan (“the Plan”) authorizing the Company to grant stock option awards to certain officers, employees and consultants under the Plan, subject to shareholder approval at the Annual Meeting of Shareholders held on September 6, 2016. The total number of shares of common stock of the Company, par value $0.01 per share (“Common Stock”), with respect to which awards may be granted pursuant to the Plan was not to exceed 2,000,000 shares.

On June 29, 2016, the Board of Directors approved the amendment to the Plan authorizing the total number of shares of common stock authorized to be subject to awards granted under the Plan to be increased to 4,000,000 shares. On September 6, 2016, at the Annual Shareholder Meeting, the Company’s shareholders approved the Plan as amended.

As of June 30, 2017, there were outstanding 1,113,000 options awarded to certain executives, key employees and advisory board members under the Plan.

The per share weighted average fair value of stock options granted during the four months ended June 30, 2017 and June 30, 2016 was $0.24 and zero, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the four months ended June 30, 2017 and June 30, 2016. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options. The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:


	June 30,
	2017		2016

Dividend yield		0.00%		0.00%
Expected Volatility		59.00-72.2%		59.00%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		4 - 5 Years		5 Years
Risk-free rate		2.17-2.48%		2.17%

- 10 -

The following table summarizes the status of the Plan:


	Four Months Ended June 30,
	2017				2016
	Shares	Weighted Average Exercise Price			Shares		Weighted Average Exercise Price

Outstanding at March 1	1,345,000	$	0.39			1,060,000	$	0.37
Granted	18,000	$	—			—	$	—
Exercised	—	$	—			—	$	—
Forfeited	250,000	$	0.36			—	$	—
Outstanding at June 30	1,113,000	$	0.39			1,060,000	$	0.37
Options exercisable at June 30,	538,000	$	0.38			—	$	—
Weighted average fair value of options granted during the period	—	$	—			—	$	—
Stock-based compensation expense	—	$	(37,385	)		—	$	50,055

Total stock-based compensation expense, net of estimated forfeitures for stock option awards totaled $(37,385) and $50,055 for the four months ended June 30, 2017 and June 30, 2016, respectively.

The weighted-average grant-date fair value of options granted during the four months ended June 30, 2017 and June 30, 2016, was $4,356 and zero, respectively. The total intrinsic value of options exercised during the four months ended June 30, 2017 and June 30, 2016, was zero for both periods.

The following table presents information pertaining to options outstanding at June 30, 2017:


Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36 - $0.41	1,113,000	5 years	$	0.39	538,000	$	0.38

As of June 30, 2017, there was $113,821 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 17 months. The total fair value of shares vested during the four months ended June 30, 2017 and June 30, 2016, was $9,300 and zero, respectively.

- 11 -

PART I – ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made and information currently available.

Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, limited liquidity, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, expanding the market of FREEDOM60^®, availability of sufficient capital to continue operations, dependence on key personnel and the outcome of litigation and regulatory investigation. When used in this report, the words “estimate,” “project,” “believe,” “may,” “will,” “anticipate,” “intend,” “expect” and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties with respect to the ability to raise capital if or when needed to develop and market new products, acceptance of and demand for new and existing products, ability to penetrate new markets, our success in enforcing and obtaining patents, obtaining required Government approvals, attracting and maintaining key personnel, succeeding in litigation claims and resolving the FDA Warning Letter that could cause the actual results to differ materially. Our actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. The Company does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Throughout this report, “RMS,” the “Company,” “we,” “us” and “our” refer to Repro Med Systems, Inc.

OVERVIEW

On March 22, 2017, the Board of Directors approved a change in the Company’s fiscal year end from February 28 to December 31. With this fiscal year end change, the Company is reporting one-time, transitional financial information for the month of March 2017 and the quarter April through June 2017.

During the four month period ended June 30, 2017, we delivered sales growth both domestically and internationally, ramped up production to keep pace with demand and found ways to lower costs. The FDA renewed our Certificate to Foreign Government which is used to communicate to foreign governments that the FDA certified that RMS meets good manufacturing practices and quality system regulations. We received registrations in new countries, launched our new flow controller in Europe and started several clinical trials with drug companies. Furthermore, we have launched a new marketing campaign, redesigned our packaging and entered the social media world to help extend our brand awareness. We plan to continue to focus on global sales growth, cost control and new product development. Additionally, we continue to look for a new facility with more square footage to accommodate our expanding needs.

Our net sales results for the four months ended June 30, 2017 increased 31.1%, versus the same period last year. Part of the increase was the result of backorders of $0.4 million at February 28, 2017 which were filled during the four months ended June 30, 2017. Excluding these backorders, net sales grew 21.6% driven by organic growth both domestically and internationally, which included two large pump orders accelerated into this period and a large return of product related to a market withdrawal last year. Our selling, general and administrative costs were 4.7% lower for the four months ended June 30, 2017 compared with the same period last year. We saw a significant reduction in legal fees related to our litigation and FDA regulatory efforts. However, we cannot predict whether this trend will continue, nor can we predict the outcome of the litigation or regulatory process. We also had reductions in sales and marketing driven by reduced recruiting and consulting fees that were incurred last year related to our website redesign, public relations, sales training and lead generation efforts and the timing of spend for current year marketing initiatives. Offsetting these savings were increased salary and related benefit costs in our regulatory department due to headcount to support our regulatory compliance requirements.

- 12 -

RESULTS OF OPERATIONS

Four Months Ended June 30, 2017 compared to June 30, 2016

Net Sales

The following table summarizes our net sales for the four months ended June 30, 2017 and 2016:


	Four Months Ended June 30,				Change from Prior Year			% of Sales
	2017		2016		$		%	2016	2015
Sales
Domestic	$	4,254,605	$	3,287,740	$	966,865	29.4%	79.7%	80.7%
International		1,084,471		784,453		300,018	38.2%	20.3%	19.3%
Total	$	5,339,076	$	4,072,193	$	1,266,883	31.1%

Total net sales increased $1.3 million or 31.1% for the four months ended June 30, 2017 compared with the same period last year. Part of the increase came from fulfilling backorders of $0.4 million at February 28, 2017. Excluding these backorders, net sales increased 21.6%. This growth was driven by both domestic and international sales, resulting from increased organic growth in all product categories. The launch of a new drug generated increased needle sales as customers built inventory, two large pump orders were accelerated forward into this period and last year included a large return of product related to a market withdrawal. We continue to concentrate the majority of our efforts in our infusion product lines, specifically towards new applications in both domestic and international markets. We continue to pursue registrations in new countries, although revenue realization could take up to eighteen months from the initial registration efforts. We also continue to expand our sales efforts into the antibiotic market.

Gross Profit

Our gross profit for the four months ended June 30, 2017 and 2016 is as follows:


	Four Months Ended June 30,				Change from Prior Year
	2017		2016		$		%
Gross Profit	$	3,270,095	$	2,616,826	$	653,269	25.0%
Stated as a Percentage of Net Sales		61.2%		64.3%

Gross profit increased $0.7 million or 25.0% in the four months ended June 30, 2017, compared to the same period in 2016. This increase in the quarter was mostly driven by the increase in net revenues of $1.3 million. Partially offsetting this increase was higher production costs related to scrap during quality inspections as we work to implement a nondestructive testing protocol. Additionally, we had higher sterilization costs due to more frequent cycles required to meet demand and backlog and increased shipping costs due to the backlog. We also had higher production salary and related benefits costs from overtime and the addition of a second shift to meet increased demand.

Selling, general and administrative and Research and development

Our selling, general and administrative expenses and research and development costs for the four months ended June 30, 2017 and 2016 are as follows:


	Four Months Ended June 30,				Change from Prior Year
	2017		2016		$			%
Selling, general and administrative	$	2,643,043	$	2,773,202		(130,159	)	(4.7%	)
Research and development		32,712		71,938		(39,226	)	(54.5%	)
	$	2,675,755	$	2,845,140		(169,385	)	(-6.0%	)
Stated as a Percentage of Net Sales		50.1%		69.9%

- 13 -

Selling, general and administrative expenses decreased $0.1 million, or 4.7%, during the four months ended June 30, 2017 compared to the same period last year. The decrease was the result of a significant reduction in legal fees related to our litigation and regulatory efforts. However, we cannot predict whether this trend will continue, nor can we predict the outcome of the litigation. We are making every effort to manage the spend on professional fees while making sure we do whatever is necessary to achieve a positive outcome regarding out litigation and FDA matters. We also had reductions in sales and marketing driven by reduced recruiting fees, lower consulting fees related to our website redesign last year, timing of spend this year on marketing initiatives and lower salary and related costs due to attrition. Partially offsetting these savings were increased costs in our regulatory department due to headcount to support our regulatory compliance requirements.

Research and development expense decreased by 54.5%, primarily due to attrition for the period. We are committed to our research and development activities and are actively searching to replace the open position. We continue to actively pursue new product development and enhance existing product lines based on demand from the marketplace which includes feedback from sales and marketing at RMS and our distributors, the RMS clinical advisory panel, and our strategic business partners. We believe that such efforts have been useful in helping us to maintain our competitive position, increase revenue from our existing customer base and expand our market reach. Although our research and development efforts have allowed us to develop the Freedom60, our HIgH-Flo needle sets, and the FreedomEdge^® in 2015, there can be no assurance that our research and development will result in additional commercially successful products.

Depreciation and amortization

Depreciation and amortization expense increased by 6.0% up to $102,357 in the four months ended June 30, 2017 compared with $96,577 in the four months ended June 30, 2016 as a result of continued investment in new computer equipment for both administrative support and for production requirements, patent applications and maintenance of existing patents.

Net Income/(Loss)


	Four Months Ended June 30,					Change from Prior Year
	2017		2016			$
Net Income/(Loss)	$	360,833	$	(205,882	)	$	566,715
Stated as a Percentage of Net Sales		6.8%		(5.1%	)

Our net income for the four months ended June 30, 2017 was $0.4 million compared to a net loss of $0.2 million for the four months ended June 30, 2016. This $0.6 million increase was mostly a result of the increase in sales and reduced selling, general and administrative expenses as described above. Additionally, the Company recognized a $54,659 foreign exchange gain for the period.

LIQUIDITY AND CAPITAL RESOURCES

Our principal source of liquidity is our cash of $3.0 million as of June 30, 2017, and cash flows from operations. Our principal source of operating cash inflows is from sales of our products to customers. Our principal cash outflows relate to the purchase and production of inventory and related costs, selling, general and administrative expenses, research and development costs, capital expenditures and patent costs.

We believe that as of June 30, 2017, cash on hand and cash expected to be generated from future operating activities will be sufficient to fund our operations, including further research and development and capital expenditures for the next 12 months. We believe the FREEDOM System continues to find a solid following in the SCIg market, and this market is expected to continue to increase both domestically and internationally. In addition, we expect many of the SCIg providers, and others, will see benefit in using the FREEDOM System for additional uses such as antibiotics, chemotherapeutics, and pain medications.

We continue to be in litigation with a competitor, EMED Technologies Corp. (“EMED”) and have incurred a significant amount of legal fees in connection with that process. Although the Company believes it has meritorious claims and defenses in the actions and proceedings, their outcomes cannot be predicted with any certainty. If any of these actions against the Company are successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

- 14 -

Cash Flows

The following table summarizes our cash flows:


	Four Months Ended June 30, 2017			Four Months Ended June 30, 2016
Net cash used in operating activities	$	(236,636	)	$	(544,137	)
Net cash used in investing activities	$	(74,761	)	$	(103,634	)
Net cash used in financing activities	$	(19,360	)	$	(1,105	)

Operating Activities

Net cash used in operating activities of $0.2 million for the four months ended June 30, 2017 was primarily attributable to our increase in accounts receivable of $0.4 million and a decrease in accounts payable of $0.5 million mostly due to the payment of legal fees accrued for at February 28, 2017. Partially offsetting these items were the net income of $0.4 million, non-cash charges of $0.1 million for depreciation and amortization of long lived tangible and intangible assets and a decrease in income tax receivable of $0.2 million.

Net cash used in operating activities of $0.6 million for the four months ended June 30, 2016 was primarily attributable to the operating loss of $0.2 million, an increase in accounts receivable of $0.4 million, an increase in prepaid expense of $0.1 million mostly due to an income tax receivable of $0.1 million due to the loss in the period, all partially offset by non-cash charges of $0.1 million for depreciation and amortization of long lived tangible and intangible assets, stock based compensation expense of $69,714 and an increase in accounts payable of $0.2 million mostly due to raw material purchases and legal fees.

Investing Activities

Our net cash used in investing activities of $0.1 million for the four months ended June 30, 2017 and June 30, 2016 was primarily attributable to our continued investment in capital assets mostly related to production and for new patent applications and maintenance of existing patents.

Financing Activities

Our net cash used in financing activities was $19,360 and $1,105 for the four months ended June 30, 2017 and June 30, 2016, respectively, both the result of the repurchase of shares of the Company’s common stock.

FDA

RMS had an inspection by the FDA in June 2015, which included, among other items, a review of customer complaints, quality controls, quality assurance and documentation. The FDA inspection was then expanded as a consequence of an extensive “trade complaint” filed on behalf of a competitor which resulted in the issuance of an FDA FORM 483. Eight months later, on February 29, 2016 we received a Warning Letter. The Company responded and replied numerous times to the Warning Letter from March 18, 2016 on, and underwent a follow up inspection on November 29, 2016. On December 16, 2016, the FDA issued another FDA FORM 483, to which the Company provided a written response on January 9, 2017 and provided a supplemental response on March 17, 2017 and April 24, 2017. On April 25, 2017, RMS met with the FDA Center for Devices and Radiological Health (“CDRH”) Compliance team and the New York District Office to discuss the final resolution of Warning Letter closure. On May 23, 2017, the Compliance Office of CDRH issued a letter to RMS to acknowledge that RMS had successfully addressed all quality and regulatory issues cited in the Warning Letter. Prior to closing the Warning Letter, the FDA also needs to complete its review of our premarket submission (a pending 510(k)), which was accepted for review on May 17, 2017. On June 30, 2017, RMS received a written response regarding our pending 510(k) submission, and RMS is working with the Office for Device Evaluation of CDRH to address those questions in order receive the 510(k) clearance as expeditiously as possible.

- 15 -

On April 19, 2017, the FDA renewed our Certificate to Foreign Government which is used to communicate to foreign governments that the FDA certified that RMS meets good manufacturing practices and quality system regulations.

Although the Company is attempting to meet all of the FDA requirements, we cannot be certain that our actions will be deemed satisfactory by the FDA and this could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

- 16 -

this update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by update 2014-09). In December 2016, the FASB issued ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which represents changes to make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This update is the final, combined version of Proposed Accounting Standards Updates 2016-240 and 2016-320 (both entitled Technical Corrections and Improvements), which have been deleted. Based upon our initial evaluation, we do not expect the adoption of the standard and related amendments to have a material effect on our financial condition or results of operations.

PART I – ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not Applicable.

PART I – ITEM 4. CONTROLS AND PROCEDURES.

The Company’s management, including the Company’s Principal Executive Officer and Principal Financial Officer, have evaluated the effectiveness of the Company’s disclosure controls and procedures as such is defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based upon their evaluations, the Principal Executive Officer and Principal Financial Officer concluded that, as of the end of the period covered by this report, the Company’s disclosure controls and procedures were effective for the purpose of ensuring that the information required to be disclosed in the reports that the Company files or submits under the Exchange Act with the Securities and Exchange Commission (the “SEC”) (1) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) is accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in the Company’s internal control over financial reporting during the quarter ended June 30, 2017, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II – OTHER INFORMATION

PART II – ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

On October 21, 2015, the Board of Directors of the Company approved non-employee director compensation of $25,000 each annually, to be paid quarterly half in cash and half in common stock, beginning September 1, 2015. The number of shares to be issued each quarter is calculated based upon the closing price of the common stock on the last day of each fiscal quarter as reported by the OTCQX. The Company issued an aggregate of 44,118 shares of common stock to its non-employee directors during the four month period ended June 30, 2017.

As of June 30, 2017, the Company issued an aggregate of 13,555 shares of common stock to Dr. Fred Ma, its Chief Medical Officer, under the terms of his employment agreement.

- 17 -

The following table provides information regarding repurchases by the Company of its common stock during the three month period ended June 30, 2017:

Issuer Purchases of Common Stock


				Total Number	Maximum
				of Shares	Number of
	Total			Purchased as	Shares that May
	Number of	Average		Part of Publicly	Yet Be
	Shares	Price Paid		Announced	Purchased
Period (1)	Purchased (2)	Per Share		Plan (3)	Under the Plan (3)
March 1, 2017 – March 31, 2017	—		—	—	1,603,394
April 1, 2017 – April 30, 2017	—		—	—	1,603,394
May 1, 2017 – May 31, 2017	44,000	$	0.44	—	1,603,394
June 1, 2017 – June 30, 2017	—		—	—	1,603,394
Total	44,000	$	0.44	—

__________


(1)	Monthly information is presented by reference to the Company’s fiscal months for the four months ended June 30, 2017.

(2)	In May 2017, the Company repurchased 44,000 shares of the Company’s common stock owned by two terminated employees at an aggregate purchase price of $19,360.

(3)	On September 30, 2015, RMS’s Board of Directors authorized the Company to make open market purchases of up to 2,000,000 shares of the Company’s Outstanding Common Stock. The purchases are made through a broker designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the rules of the Securities and Exchange Commission for such repurchases. As of June 30, 2017, the Company had repurchased 396,606 shares at an average price of $0.45 under the program. The management of the Company decided to discontinue repurchasing its outstanding common stock under the program for an undetermined period of time to utilize cash for capital investments needed to expand the business. There is no expiration date to the program.

On September 30, 2015, the Board of Directors approved the 2015 Stock Option Plan authorizing the Company to grant awards to certain employees under the plan at fair market value, which was approved by shareholders at the Annual Meeting held on September 6, 2016. The total number of shares of Common Stock, with respect to which awards may be granted pursuant to the Plan, shall not exceed 4,000,000 shares. As of June 30, 2017, there were outstanding 1.1 million options awarded to certain executives, key employees and advisory board members under the Plan.

All of the securities issued by the Company as described in this Item were issued in reliance on the exemption from registration under Section 4(2) under the Securities Act of 1933, as amended.

PART II – ITEM 6. EXHIBITS.


31.1	Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

31.2	Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act 2002

32.1	Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

32.2	Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 2002

101*	Interactive Data Files of Financial Statements and Notes.

* In accordance with Regulation S-T, the Interactive Data Files in Exhibit 101 to the Quarterly Report on Form 10-Q shall be deemed “furnished” and not “filed”.

- 18 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	REPRO MED SYSTEMS, INC.

August 4, 2017	/s/ Andrew I. Sealfon
	Andrew I. Sealfon, President, Chairman of the Board, Director, Chief Executive Officer

August 4, 2017	/s/ Karen Fisher
	Karen Fisher, Chief Financial Officer and Treasurer

- 19 -

EX-31 2 ex_31-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 31.1

RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

I, Andrew I. Sealfon, Principal Executive Officer, certify that:


1)	I have reviewed Form 10-Q of Repro Med Systems, Inc. (the “Report”);

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2017

/s/ Andrew I. Sealfon

Andrew I. Sealfon

Chief Executive Officer

EX-31 3 ex_31-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

EXHIBIT 31.2

RULE 13A-14(A) / 15D-14(A) CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

I, Karen Fisher, Principal Financial Officer, certify that:


1)	I have reviewed Form 10-Q of Repro Med Systems, Inc. (the “Report”);

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4)	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5)	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 4, 2017

/s/ Karen Fisher

Karen Fisher

Chief Financial Officer and Treasurer

EX-32 4 ex_32-1.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro Med Systems, Inc. (the “Company”) on Form 10-Q (the “Report”) for the period ending June 30, 2017 as filed with the Securities and Exchange Commission, I, Andrew I. Sealfon, Principal Executive Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 4, 2017

/s/ Andrew I. Sealfon

Andrew I. Sealfon

Chief Executive Officer

EX-32 5 ex_32-2.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350

AS ADDED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro Med Systems, Inc. (the “Company”) on Form 10-Q (the “Report”) for the period ending June 30, 2017 as filed with the Securities and Exchange Commission, I, Karen Fisher, Principal Financial Officer, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:


	(1)	the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 4, 2017

/s/ Karen Fisher

Karen Fisher

Chief Financial Officer and Treasurer

EX-101.INS 6 repr-20170630.xml XBRL INSTANCE FILE 0000704440 2017-03-01 2017-06-30 0000704440 2017-08-04 0000704440 repr:ClinicalResearchAndSupportServicesConsultingAgreementMember us-gaap:ProductMember us-gaap:DirectorMember 2013-12-19 2013-12-20 0000704440 repr:ClinicalResearchAndSupportServicesConsultingAgreementMember us-gaap:ProductMember us-gaap:DirectorMember 2013-12-20 0000704440 repr:ConsultingAgreementMember us-gaap:ChiefOperatingOfficerMember 2015-10-20 2015-10-21 0000704440 repr:ConsultingAgreementMember us-gaap:ChiefOperatingOfficerMember 2015-12-31 2016-01-01 0000704440 repr:ConsultingAgreementMember repr:CyrilNarishkinMember 2016-06-23 2016-06-24 0000704440 repr:ClinicalResearchAndSupportServicesConsultingAgreementMember us-gaap:DirectorMember 2017-03-01 2017-06-30 0000704440 repr:ClinicalResearchAndSupportServicesConsultingAgreementMember us-gaap:DirectorMember 2016-03-01 2016-06-30 0000704440 repr:ConsultingAgreementMember repr:CyrilNarishkinMember 2017-03-01 2017-06-30 0000704440 repr:ConsultingAgreementMember repr:CyrilNarishkinMember 2016-03-01 2016-06-30 0000704440 repr:LeaseAgreementMember us-gaap:AirTransportationEquipmentMember us-gaap:PresidentMember 2017-03-01 2017-06-30 0000704440 repr:LeaseAgreementMember us-gaap:AirTransportationEquipmentMember us-gaap:PresidentMember 2016-03-01 2016-06-30 0000704440 repr:LeaseAgreementMember us-gaap:BuildingMember repr:Director1Member 2017-03-01 2017-06-30 0000704440 repr:LeaseAgreementMember us-gaap:BuildingMember repr:Director1Member 2016-03-01 2016-06-30 0000704440 2016-02-29 0000704440 us-gaap:LandMember 2017-02-28 0000704440 us-gaap:BuildingMember 2017-02-28 0000704440 repr:FurnitureOfficeEquipmentAndLeaseholdImprovementsMember 2017-02-28 0000704440 repr:ManufacturingEquipmentAndToolingMember 2017-02-28 0000704440 2017-02-28 0000704440 us-gaap:LandMember 2017-06-30 0000704440 us-gaap:BuildingMember 2017-06-30 0000704440 repr:FurnitureOfficeEquipmentAndLeaseholdImprovementsMember 2017-06-30 0000704440 repr:ManufacturingEquipmentAndToolingMember 2017-06-30 0000704440 2017-06-30 0000704440 repr:ShareRepurchaseProgramMember 2015-09-30 0000704440 repr:ShareRepurchaseProgramMember 2017-06-30 0000704440 repr:ShareRepurchaseProgramMember 2017-03-01 2017-06-30 0000704440 repr:StockOptionPlan2015Member 2017-03-01 2017-06-30 0000704440 repr:StockOptionPlan2015Member 2016-03-01 2016-06-30 0000704440 repr:StockOptionPlan2015Member us-gaap:MinimumMember 2017-03-01 2017-06-30 0000704440 repr:StockOptionPlan2015Member us-gaap:MaximumMember 2017-03-01 2017-06-30 0000704440 repr:StockOptionPlan2015Member 2016-02-29 0000704440 repr:StockOptionPlan2015Member 2017-02-28 0000704440 repr:StockOptionPlan2015Member 2017-06-30 0000704440 repr:StockOptionPlan2015Member 2016-06-30 0000704440 repr:StockOptionPlan2015Member repr:Dollar0.36ToDollar0.41Member 2017-03-01 2017-06-30 0000704440 repr:StockOptionPlan2015Member repr:Dollar0.36ToDollar0.41Member 2017-06-30 0000704440 repr:StockOptionPlan2015Member 2015-09-30 0000704440 repr:IndependentDirectorsMember 2015-10-20 2015-10-21 0000704440 repr:StockOptionPlan2015Member 2016-06-29 0000704440 repr:StockOptionPlan2015Member repr:KeyEmployeesMember 2017-03-01 2017-06-30 0000704440 2017-03-01 2017-03-31 0000704440 2016-03-01 2016-03-31 0000704440 2017-04-01 2017-06-30 0000704440 2016-04-01 2016-06-30 0000704440 2016-03-01 2016-06-30 0000704440 2016-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure repr:Segment REPRO MED SYSTEMS INC 0000704440 10-Q 2017-06-30 false No No Yes Q2 2017 37834871 --12-31 Smaller Reporting Company

420000

0.20

0.45

P3Y

7000

16000

Half was to be paid in cash and half was to be paid in shares of common stock.

Seventy-five percent was to be paid in cash and twenty-five percent was to be paid in shares of common stock.

Paid quarterly half in cash and half in common stock.

5668

7167

44168

118000

16236 15825 11042 11042

96542

43393

54030

171094

1022942

1003166

2251232

54030

171094

1048818

1031207

2305149

1319140

1403685

932092

901464

2000000

396606

0.0000

0.5900

0.722

P5Y

P4Y

P5Y

0.0217

0.0248

1060000

1345000

1113000

1060000

18000

1113000

250000

538000

0.37

0.39

0.37

0.36

0.38

-37385

50055

0.24

0.00

1113000

P5Y

0.39

538000

0.38

2000000

4000000

0.01

25000

4356 0

113821

9300

P17M

4201948

3313265

2982508

3553072

262314

262315

1502030

1899622

1353703

1267214

172457

175955

229667

6779724

6641326

426943

429974

31490

31582

8170249

8004346

22481

772428

279130

417357

353997

177018

212083

1384

1389284

869075

22496

15002

82422

95133

1494202

979210

405584

405721

4129726

4117845

2484941

2845774

7020251 7369340

344204

6676047

7025136

8170249

8004346

18046

13046

180137

188735

75000000

40558429

40572102

37821198

37834871

2737231

5339076

1509619

1276299

3829457

2795894

4072193

2068981

536823

446618

1532158

1008749

1455367

3270095

972796

829681

2297299

1787145

2616826

2643043

637707

655043

2005336

2118159

2773202

32712

7872

14535

24840

57403

71938

102357

25576

23536

76781

73041

96577

2778112

671155

693114

2106957

2248603

2941717

491983

301641

136567

190342

-461458

-324891

54659

19988

36673

34671

-24340

12333

743

322

321

421

752

1073

55402

20310

36994

35092

-23588

13406

547385

321951

173561

225434

-485046

-311485

360833

212361

114330

148472

-320212

-205882

0.01

-0.01

0.01

-0.01

37824189

37821198

37966501

37825209

37964985

37965370

37877694

37847628

37966501

37891306

37964985

37965370

186552

109590

59231

76962

-164834

-105603

NOTE 1  NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   NATURE OF OPERATIONS   REPRO MED SYSTEMS, INC. (the “Company”, “RMS”, or “we”) designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality management systems.  The Company operates as one segment.   FISCAL YEAR END   On March 22, 2017, the Board of Directors approved a change in the Company’s fiscal year end from February 28 to December 31. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March 2017 and the quarter April through June 2017 on Form 10-Q.   BASIS OF PRESENTATION   The accompanying unaudited financial statements as of June 30, 2017, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.   In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of June 30, 2017, and the results of operations and cash flow for the four months periods ended June 30, 2017, and 2016.   The results of operations for the four months ended June 30, 2017, and 2016 are not necessarily indicative of the results to be expected for the full year.  These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the year ended February 28, 2017, as filed with the Securities and Exchange Commission on Form 10-K.   USE OF ESTIMATES IN THE FINANCIAL STATEMENTS   The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.   RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09—Compensation-Stock Compensation (Topic 718), which provides clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award.  The amendments in this update affect any entity that changes the terms or conditions of a share-based payment award. The amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017.  Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this update should be applied prospectively to an award modified on or after the adoption date.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In June 2016, FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities.  For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected.  For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down.  This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash.  The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The ASU clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP and International Financial Reporting Standards (“IFRS”) that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of the financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The amendments in this update are effective for the annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Full or modified retrospective adoption is required and early application is not permitted. On July 9, 2015, the FASB issued ASU No. 2015-14 Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date, which (a) delays the effective date of ASU 2014-09, Revenue from Contracts with Customers (Topic 606), by one year to annual periods beginning after December 15, 2017 and (b) allows early adoption of the ASU by all entities as of the original effective date for public entities.  We currently anticipate adopting the new standard using the modified retrospective method beginning January 1, 2018.  In March 2016, the FASB issued ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606); Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations and the effective date is the same as the requirements in ASU 2014-09.  In April 2016, the FASB issued ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606); Identifying Performance Obligations and Licensing, which is intended to clarify identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas and the effective date is the same as the requirements in ASU 2014-09.  In May 2016, FASB issued ASU No. 2016-12—Revenue from Contracts with Customers (Topic 606); Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis.  The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by update 2014-09).    In December 2016, the FASB issued ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which represents changes to make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities.  This update is the final, combined version of Proposed Accounting Standards Updates 2016-240 and 2016-320 (both entitled Technical Corrections and Improvements), which have been deleted.  Based upon our initial evaluation, we do not expect the adoption of the standard and related amendments to have a material effect on our financial condition or results of operations.   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).  The main difference between the current requirement under GAAP and this ASU is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases.  This ASU requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (other than leases that meet the definition of a short-term lease).  The liability will be equal to the present value of lease payments.  The asset will be based on the liability, subject to adjustment, such as for initial direct costs.  For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance.  Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases).  Classification will be based on criteria that are largely similar to those applied in current lease accounting.  For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases.  This is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted.  This ASU must be adopted using a modified retrospective transition, and provides for certain practical expedients.  Transition will require application of the new guidance at the beginning of the earliest comparative period presented.  We are currently assessing the potential impact of this ASU on our financial statements, disclosure requirements and methods of adoption.   The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.   STOCK-BASED COMPENSATION   The Company maintains a long-term incentive stock benefit plan under which it grants stock options and restricted stock to certain directors and key employees.  The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value.  The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date, over the vesting period.   RECLASSIFICATION   Certain reclassifications have been made to conform prior period data to the current presentation.  These reclassifications had no effect on reported net income.

NOTE 2  RELATED PARTY TRANSACTIONS   On December 20, 2013, we executed an agreement effective March 1, 2014, with a Company director, Dr. Mark Baker, to provide clinical research and support services related to new and enhanced applications for the FREEDOM60® Syringe Infusion System. Authorized by the Board of Directors, the agreement provides for payment of 420,000 shares of common stock valued at $0.20 per share over a three-year period.  Amortization amounted to zero and $7,000 for the four months ended June 30, 2017 and 2016, respectively.   On October 21, 2015, Cyril Narishkin was appointed to the Board of Directors and Interim Chief Operating Officer of the Company. Also effective October 21, 2015, we entered into a consulting agreement with Mr. Narishkin, to support our expanded management team and accelerate our growth opportunities under his role of Interim Chief Operating Officer.  The agreement provided for payment of $16,000 per month for eight days per month, of which half was to be paid in cash and half was to be paid in shares of common stock. Effective January 1, 2016, the agreement provided for the same payment of $16,000 per month, of which seventy-five percent was to be paid in cash and twenty-five percent was to be paid in shares of common stock.   On June 24, 2016, Cyril Narishkin executed a termination and general release agreement, which terminated his previous consulting agreement, and resigned as an officer and director for personal reasons.  Mr. Narishkin was compensated for services as a consultant through January 31, 2017 at a monthly rate of $16,000 per month for up to eight days of service a month upon request of the Company.  Mr. Narishkin’s compensation was zero and $118,000 for the four months ended June 30, 2017 and 2016, respectively. In accordance with the agreement, the Company repurchased 96,542 shares of common stock of the Company owned by Mr. Narishkin at an aggregate purchase price of $43,393.   LEASED AIRCRAFT   The Company leases an aircraft from a company controlled by Andrew Sealfon, the Company’s President and Chief Executive Officer. The lease payments were $5,668 and $7,167 for the four months ended June 30, 2017 and June 30, 2016, respectively. The original lease agreement has expired and the Company is currently on a month-to-month basis for rental payments.   BUILDING LEASE   Mr. Mark Pastreich, a director, is a principal in the entity that owns the building leased by Company. The Company is in year nineteen of a twenty-year lease. There have been no changes to lease terms since his directorship and none are expected through the life of the current lease.  With a monthly lease amount of $11,042, the lease payments were $44,168 for each of the four months ended June 30, 2017 and June 30, 2016.  The Company also paid property taxes for the four months ended June 30, 2017 and June 30, 2016 in the amount of $16,236 and $15,825, respectively.   We are currently seeking another location within a 30 mile radius from our current facility with more square footage to accommodate our expanding needs.  In addition to the increased costs of occupying a larger space, we expect to incur additional costs in connection with construction and FDA compliance with respect to the new location.  There can be no assurance that we will find a suitable location before our current lease expires on terms that are economically favorable to us or at all.

NOTE 3  PROPERTY AND EQUIPMENT   Property and equipment consists of the following at:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">June 30, 2017</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">February 28, 2017</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="width: 58%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%"> </td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 17%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Land</td> <td> </td> <td>$</td> <td style="text-align: right">54,030</td> <td> </td> <td>$</td> <td style="text-align: right">54,030</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Building</td> <td> </td> <td> </td> <td style="text-align: right">171,094</td> <td> </td> <td> </td> <td style="text-align: right">171,094</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Furniture, office equipment, and leasehold improvements</td> <td> </td> <td> </td> <td style="text-align: right">1,048,818</td> <td> </td> <td> </td> <td style="text-align: right">1,022,942</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Manufacturing equipment and tooling</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,031,207</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,003,166</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,305,149</td> <td> </td> <td> </td> <td style="text-align: right">2,251,232</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Less: accumulated depreciation</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,403,685</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,319,140</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #dedede"> <td>Property and equipment, net</td> <td> </td> <td style="border-bottom: #000000 3px double">$</td> <td style="border-bottom: #000000 3px double; text-align: right">901,464</td> <td> </td> <td style="border-bottom: #000000 3px double">$</td> <td style="border-bottom: #000000 3px double; text-align: right">932,092</td> <td> </td></tr> </table>

NOTE 4  LEGAL PROCEEDINGS   Lawyers representing EMED Technologies Corp. (“EMED”) sent RMS a letter dated, May 1, 2013, which alleged that the RMS High-Flo Butterfly design infringed a patent controlled by EMED.  RMS disputed this claim and we believed that our design did not infringe and that the EMED patent itself was not valid.  Under advice of counsel, on September 20, 2013, the Company commenced in the United States District Court for the Eastern District of California a declaratory judgment action against competitor, EMED to establish the invalidity of one of EMED’s patents and non-infringement of the Company’s needle sets. EMED answered the complaint and asserted patent infringement and unfair business practice counterclaims. The Company responded by asserting its own unfair business practice claims against EMED. Both parties have requested injunctive relief and monetary damages. Discovery is ongoing.   On June 16, 2015, the Court issued what it termed a “narrow” preliminary injunction against the Company from making certain statements regarding some of EMED’s products. On June 23, 2016, EMED filed a motion seeking to have the Company held in contempt, claiming that certain language in the Company’s device labeling does not comply with the injunction. In response to a show cause order, the Company advised the Court that the language in the Company’s labeling that EMED challenged is language that the FDA directed the Company to use in its labeling. The Court discharged the show cause order, effectively rejecting EMED’s contempt argument.   On March 24, 2016, EMED filed a motion seeking a second preliminary injunction prohibiting RMS from selling three of its products in California. The Company opposed that motion on April 19, 2016. A decision on the motion is still pending.   On June 25, 2015, EMED filed a claim of patent infringement for the second of its patents, also directed to the Company’s needle sets, in the United States District Court for the Eastern District of Texas. This second patent is related to the one concerning the Company’s declaratory judgment action. Given the close relationship between the two patents, the Company requested that the Texas suit be transferred to California. Also, based on a validity review of the patent in the U.S. Patent and Trademark Office (“USPTO”), discussed below, the Company requested the Texas suit be stayed. On May 12, 2016, the Court entered an order staying the case until after the Patent Trial and Appeal Board (“PTAB”) at the USPTO issued a final written decision regarding the validity of the patent. On January 12, 2017, the PTAB issued its final written decision invalidating the claims asserted by EMED in the Texas litigation. On January 26, 2017, the Company and EMED requested that the Texas case remain stayed pending EMED’s appeal of the PTAB’s final ruling to the Court of Appeals for the Federal Circuit (“CAFC”).   On September 11, 2015, the Company requested an ex parte reexamination of the patent in the first filed case, and on September 17, 2015 the Company requested an inter partes review (“IPR”) of the patent in the second filed case. On November 20, 2015, the USPTO instituted the ex parte reexamination request having found a substantial new question of patentability concerning EMED’s patent in the first filed case. All EMED claims have been rejected by the USPTO Examiner in a Non-Final Office Action. EMED filed a response that is awaiting consideration by the Examiner. Thus, the ex parte reexamination is ongoing. A decision to institute the IPR for EMED’s patent in the second filed case was ordered by the USPTO on February 19, 2016 having determined a reasonable likelihood all claims of the patent may be found to be unpatentable. Oral argument for the IPR was held on November 22, 2016 and a final ruling issued on January 12, 2017. In its final ruling, the PTAB held the claim asserted by EMED against the Company in the second filed case was invalid. EMED appealed the PTAB’s final ruling, and EMED’s opening brief in the CAFC was filed on June 26, 2017.  The Company is now responding.   Although the Company believes it has meritorious claims and defenses in these actions and proceedings, their outcomes cannot be predicted with any certainty. We believe that it is very likely both patents will be determined invalid, however, if any of these actions against the Company are successful, they could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

NOTE 5  STOCKHOLDERS’ EQUITY   On September 30, 2015, RMS’s Board of Directors authorized the Company to make open market purchases of up to 2,000,000 shares of the Company’s Outstanding Common Stock.  The purchases are made through a broker designated by the Company, with price, timing and volume restrictions based on average daily trading volume, consistent with the rules of the Securities and Exchange Commission for such repurchases.  As of June 30, 2017, the Company had repurchased 396,606 shares at an average price of $0.45 under the program.  The management of the Company decided to discontinue repurchasing its outstanding common stock under the program for an undetermined period of time to utilize cash for capital investments needed to expand the business.

NOTE 6  STOCK-BASED COMPENSATION   On September 30, 2015, the Board of Directors approved the 2015 Stock Option Plan (“the Plan”) authorizing the Company to grant stock option awards to certain officers, employees and consultants under the Plan, subject to shareholder approval at the Annual Meeting of Shareholders held on September 6, 2016.  The total number of shares of common stock of the Company, par value $0.01 per share (“Common Stock”), with respect to which awards may be granted pursuant to the Plan was not to exceed 2,000,000 shares.   On June 29, 2016, the Board of Directors approved the amendment to the Plan authorizing the total number of shares of common stock authorized to be subject to awards granted under the Plan to be increased to 4,000,000 shares.  On September 6, 2016, at the Annual Shareholder Meeting, the Company’s shareholders approved the Plan as amended.   As of June 30, 2017, there were outstanding 1,113,000 options awarded to certain executives, key employees and advisory board members under the Plan.   On October 21, 2015, the Board of Directors of the Company approved non-employee director compensation of $25,000 each annually, to be paid quarterly half in cash and half in common stock, beginning September 1, 2015.   The per share weighted average fair value of stock options granted during the four months ended June 30, 2017 and June 30, 2016 was $0.24 and zero, respectively. The fair value of each award is estimated on the grant date using the Black-Scholes option pricing model with the following weighted average assumptions used for grants in the four months ended June 30, 2017 and June 30, 2016. Historical information was the primary basis for the selection of the expected volatility, expected dividend yield and the expected lives of the options.  The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="background-color: #ffffff"> <td> </td> <td> </td> <td colspan="5" style="border-bottom: #000000 1px solid; text-align: center">June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">2017</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="width: 51%"> </td> <td style="width: 3%"> </td> <td style="width: 2%"> </td> <td style="width: 18%"> </td> <td style="width: 5%"> </td> <td style="width: 2%"> </td> <td style="width: 17%"> </td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00%</td> <td> </td> <td> </td> <td style="text-align: right">0.00%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Expected Volatility</td> <td> </td> <td> </td> <td style="text-align: right">59.00-72.2%</td> <td> </td> <td> </td> <td style="text-align: right">59.00%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Weighted-average volatility</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Expected dividends</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Expected term (in years)</td> <td> </td> <td> </td> <td style="text-align: right">4 - 5 Years</td> <td> </td> <td> </td> <td style="text-align: right">5 Years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Risk-free rate</td> <td> </td> <td> </td> <td style="text-align: right">2.17-2.48%</td> <td> </td> <td> </td> <td style="text-align: right">2.17%</td> <td> </td></tr> </table>   The following table summarizes the status of the Plan:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="10" style="border-bottom: #000000 1px solid; text-align: center">Four Months Ended June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="4" style="border-bottom: #000000 1px solid; text-align: center">2017</td> <td> </td> <td colspan="5" style="border-bottom: #000000 1px solid; text-align: center">2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Shares</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Shares</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td style="width: 46%">Outstanding at March 1</td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%">1,345,000</td> <td style="width: 4%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">0.39</td> <td style="width: 4%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%">1,060,000</td> <td style="width: 4%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">0.37</td> <td style="width: 1%"> </td></tr> <tr style="background-color: #ffffff"> <td style="vertical-align: bottom">Granted</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">18,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #e6e6e6"> <td style="vertical-align: bottom">Exercised</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #ffffff"> <td style="vertical-align: bottom">Forfeited</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">250,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.36</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Outstanding at June 30</td> <td> </td> <td style="text-align: right">1,113,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.39</td> <td> </td> <td> </td> <td style="text-align: right">1,060,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.37</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Options exercisable at June 30,</td> <td> </td> <td style="text-align: right">538,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.38</td> <td>  </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td style="padding-left: 17px; text-indent: -17px">Weighted average fair value of options granted during the period</td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Stock-based compensation expense</td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">(37,385</td> <td>)</td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">50,055</td> <td> </td></tr> </table>   Total stock-based compensation expense, net of estimated forfeitures for stock option awards totaled $(37,385) and $50,055 for the four months ended June 30, 2017 and June 30, 2016, respectively.   The weighted-average grant-date fair value of options granted during the four months ended June 30, 2017 and June 30, 2016, was $4,356 and zero, respectively.  The total intrinsic value of options exercised during the four months ended June 30, 2017 and June 30, 2016, was zero for both periods.   The following table presents information pertaining to options outstanding at June 30, 2017:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="border-bottom: #000000 1px solid">Range of Exercise Price</td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Number Outstanding</td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Remaining Contractual Life</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Number Exercisable</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="width: 30%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%"> </td> <td style="width: 2%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>$0.36 - $0.41</td> <td> </td> <td style="text-align: right">1,113,000</td> <td> </td> <td style="text-align: center">5 years</td> <td> </td> <td>$</td> <td style="text-align: right">0.39</td> <td> </td> <td style="text-align: right">538,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.38</td> <td> </td></tr> </table>   As of June 30, 2017, there was $113,821 of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of 17 months. The total fair value of shares vested during the four months ended June 30, 2017 and June 30, 2016, was $9,300 and zero, respectively.

NATURE OF OPERATIONS   REPRO MED SYSTEMS, INC. (the “Company”, “RMS”, or “we”) designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality management systems.  The Company operates as one segment.

BASIS OF PRESENTATION   The accompanying unaudited financial statements as of June 30, 2017, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements.   In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of June 30, 2017, and the results of operations and cash flow for the four months periods ended June 30, 2017, and 2016.   The results of operations for the four months ended June 30, 2017, and 2016 are not necessarily indicative of the results to be expected for the full year.  These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the year ended February 28, 2017, as filed with the Securities and Exchange Commission on Form 10-K.

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS   The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS   In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09—Compensation-Stock Compensation (Topic 718), which provides clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award.  The amendments in this update affect any entity that changes the terms or conditions of a share-based payment award. The amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017.  Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this update should be applied prospectively to an award modified on or after the adoption date.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In June 2016, FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities.  For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected.  For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down.  This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash.  The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years.  The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption.   In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The ASU clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP and International Financial Reporting Standards (“IFRS”) that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of the financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The amendments in this update are effective for the annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Full or modified retrospective adoption is required and early application is not permitted. On July 9, 2015, the FASB issued ASU No. 2015-14 Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date, which (a) delays the effective date of ASU 2014-09, Revenue from Contracts with Customers (Topic 606), by one year to annual periods beginning after December 15, 2017 and (b) allows early adoption of the ASU by all entities as of the original effective date for public entities.  We currently anticipate adopting the new standard using the modified retrospective method beginning January 1, 2018.  In March 2016, the FASB issued ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606); Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations and the effective date is the same as the requirements in ASU 2014-09.  In April 2016, the FASB issued ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606); Identifying Performance Obligations and Licensing, which is intended to clarify identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas and the effective date is the same as the requirements in ASU 2014-09.  In May 2016, FASB issued ASU No. 2016-12—Revenue from Contracts with Customers (Topic 606); Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis.  The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by update 2014-09).    In December 2016, the FASB issued ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which represents changes to make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities.  This update is the final, combined version of Proposed Accounting Standards Updates 2016-240 and 2016-320 (both entitled Technical Corrections and Improvements), which have been deleted.  Based upon our initial evaluation, we do not expect the adoption of the standard and related amendments to have a material effect on our financial condition or results of operations.   In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842).  The main difference between the current requirement under GAAP and this ASU is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases.  This ASU requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (other than leases that meet the definition of a short-term lease).  The liability will be equal to the present value of lease payments.  The asset will be based on the liability, subject to adjustment, such as for initial direct costs.  For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance.  Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases).  Classification will be based on criteria that are largely similar to those applied in current lease accounting.  For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases.  This is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted.  This ASU must be adopted using a modified retrospective transition, and provides for certain practical expedients.  Transition will require application of the new guidance at the beginning of the earliest comparative period presented.  We are currently assessing the potential impact of this ASU on our financial statements, disclosure requirements and methods of adoption.   The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.

STOCK-BASED COMPENSATION   The Company maintains a long-term incentive stock benefit plan under which it grants stock options and restricted stock to certain directors and key employees.  The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value.  The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date, over the vesting period.

RECLASSIFICATION   Certain reclassifications have been made to conform prior period data to the current presentation.  These reclassifications had no effect on reported net income.

7000

7615

69714

7493

12711

-15144

-5000

-10312

392592

376551

-86489

-1575

-118652

108855

-493297

186109

35065

-21489

-63360

-67383

1384

-92003

-236636

-544137

63133

74549

11628

29085

-74761

-103634

1105

-19360

-1105

-330757

-648876

90000

45000

24718

Property and equipment consists of the following at:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">June 30, 2017</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">February 28, 2017</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="width: 58%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 17%"> </td> <td style="width: 3%"> </td> <td style="width: 1%"> </td> <td style="width: 17%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Land</td> <td> </td> <td>$</td> <td style="text-align: right">54,030</td> <td> </td> <td>$</td> <td style="text-align: right">54,030</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Building</td> <td> </td> <td> </td> <td style="text-align: right">171,094</td> <td> </td> <td> </td> <td style="text-align: right">171,094</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Furniture, office equipment, and leasehold improvements</td> <td> </td> <td> </td> <td style="text-align: right">1,048,818</td> <td> </td> <td> </td> <td style="text-align: right">1,022,942</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Manufacturing equipment and tooling</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,031,207</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,003,166</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,305,149</td> <td> </td> <td> </td> <td style="text-align: right">2,251,232</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Less: accumulated depreciation</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,403,685</td> <td> </td> <td style="border-bottom: #000000 1px solid"> </td> <td style="border-bottom: #000000 1px solid; text-align: right">1,319,140</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #dedede"> <td>Property and equipment, net</td> <td> </td> <td style="border-bottom: #000000 3px double">$</td> <td style="border-bottom: #000000 3px double; text-align: right">901,464</td> <td> </td> <td style="border-bottom: #000000 3px double">$</td> <td style="border-bottom: #000000 3px double; text-align: right">932,092</td> <td> </td></tr> </table>

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="background-color: #ffffff"> <td> </td> <td> </td> <td colspan="5" style="border-bottom: #000000 1px solid; text-align: center">June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">2017</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="width: 51%"> </td> <td style="width: 3%"> </td> <td style="width: 2%"> </td> <td style="width: 18%"> </td> <td style="width: 5%"> </td> <td style="width: 2%"> </td> <td style="width: 17%"> </td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Dividend yield</td> <td> </td> <td> </td> <td style="text-align: right">0.00%</td> <td> </td> <td> </td> <td style="text-align: right">0.00%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Expected Volatility</td> <td> </td> <td> </td> <td style="text-align: right">59.00-72.2%</td> <td> </td> <td> </td> <td style="text-align: right">59.00%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Weighted-average volatility</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Expected dividends</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Expected term (in years)</td> <td> </td> <td> </td> <td style="text-align: right">4 - 5 Years</td> <td> </td> <td> </td> <td style="text-align: right">5 Years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Risk-free rate</td> <td> </td> <td> </td> <td style="text-align: right">2.17-2.48%</td> <td> </td> <td> </td> <td style="text-align: right">2.17%</td> <td> </td></tr> </table>

The following table summarizes the status of the Plan:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="10" style="border-bottom: #000000 1px solid; text-align: center">Four Months Ended June 30,</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td colspan="4" style="border-bottom: #000000 1px solid; text-align: center">2017</td> <td> </td> <td colspan="5" style="border-bottom: #000000 1px solid; text-align: center">2016</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Shares</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Shares</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td> </td> <td> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td style="width: 46%">Outstanding at March 1</td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%">1,345,000</td> <td style="width: 4%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 9%">0.39</td> <td style="width: 4%"> </td> <td style="width: 1%"> </td> <td style="text-align: right; width: 9%">1,060,000</td> <td style="width: 4%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">0.37</td> <td style="width: 1%"> </td></tr> <tr style="background-color: #ffffff"> <td style="vertical-align: bottom">Granted</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">18,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #e6e6e6"> <td style="vertical-align: bottom">Exercised</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #ffffff"> <td style="vertical-align: bottom">Forfeited</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">250,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">0.36</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: top">$</td> <td style="vertical-align: bottom; text-align: right">—</td> <td style="vertical-align: bottom"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>Outstanding at June 30</td> <td> </td> <td style="text-align: right">1,113,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.39</td> <td> </td> <td> </td> <td style="text-align: right">1,060,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.37</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Options exercisable at June 30,</td> <td> </td> <td style="text-align: right">538,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.38</td> <td>  </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td style="padding-left: 17px; text-indent: -17px">Weighted average fair value of options granted during the period</td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">—</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td>Stock-based compensation expense</td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">(37,385</td> <td>)</td> <td> </td> <td style="text-align: right">—</td> <td> </td> <td>$</td> <td style="text-align: right">50,055</td></tr> </table>

The following table presents information pertaining to options outstanding at June 30, 2017:   <table cellspacing="0" cellpadding="0" style="margin-top: 0px; font-size: 10pt"> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="border-bottom: #000000 1px solid">Range of Exercise Price</td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Number Outstanding</td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Remaining Contractual Life</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td style="border-bottom: #000000 1px solid; text-align: center">Number Exercisable</td> <td> </td> <td colspan="2" style="border-bottom: #000000 1px solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #ffffff"> <td style="width: 30%"> </td> <td style="width: 1%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%"> </td> <td style="width: 2%"> </td> <td style="width: 12%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%"> </td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #e6e6e6"> <td>$0.36 - $0.41</td> <td> </td> <td style="text-align: right">1,113,000</td> <td> </td> <td style="text-align: center">5 years</td> <td> </td> <td>$</td> <td style="text-align: right">0.39</td> <td> </td> <td style="text-align: right">538,000</td> <td> </td> <td>$</td> <td style="text-align: right">0.38</td> <td> </td></tr> </table>

REPR

FISCAL YEAR END    On March 22, 2017, the Board of Directors approved a change in the Company’s fiscal year end from February 28 to December 31. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March 2017 and the quarter April through June 2017 on Form 10-Q.

EX-101.SCH 7 repr-20170630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LEGAL PROCEEDINGS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - STOCK-BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK-BASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - STOCK-BASED COMPENSATION (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 repr-20170630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 repr-20170630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 repr-20170630_lab.xml XBRL LABEL FILE Type of Arrangement and Non-arrangement Transactions [Axis] Clinical Research & Support Services Consulting Agreement [Member] Products and Services [Axis] FREEDOM60 Syringe Infusion System [Member] Related Party [Axis] Dr. Mark Baker [Member] Consulting Agreement [Member] Mr. Cyril Narishkin [Member] Mr. Cyril Narishkin (Consultant) [Member] Lease Arrangement, Type [Axis] Lease Agreement [Member] Property, Plant and Equipment, Type [Axis] Aircraft [Member] Mr. Andrew I. Sealfon [Member] Building [Member] Mr. Mark Pastreich [Member] Land [Member] Furniture, Office Equipment, and Leasehold Improvements [Member] Manufacturing Equipment and Tooling [Member] Share Repurchase Program [Axis] Share Repurchase Program [Member] Plan Name [Axis] 2015 Stock Option Plan [Member] Range [Axis] Minimum [Member] Maximum [Member] Exercise Price Range [Axis] $0.36 - $0.41 [Member] Independent Directors ( Dr. Mark Baker, Mr. Mark Pastreich, Mr. Arthur Radin and Mr. Cyril Narishkin) [Member] Key Employees [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Trading Symbol Document Period End Date Amendment Flag Current Fiscal Year End Date Entity a Well-known Seasoned Issuer Entity a Voluntary Filer Entity's Reporting Status Current Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS Cash and cash equivalents Certificates of deposit Accounts receivable less allowance for doubtful accounts of $13,046 at June 30, 2017 and $18,046 at February 28, 2017 Inventory Tax Receivable Prepaid expenses TOTAL CURRENT ASSETS Property and equipment, net Patents, net of accumulated amortization of $188,735 and $180,137 at June 30, 2017 and February 28, 2017, respectively Other assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Deferred capital gain - current Accounts payable Accrued expenses Accrued payroll and related taxes Accrued tax liability TOTAL CURRENT LIABILITIES Deferred capital gain - long term Deferred tax liability TOTAL LIABILITIES STOCKHOLDERS' EQUITY Common stock, $0.01 par value; 75,000,000 shares authorized, 40,572,102 and 40,558,429 shares issued, 37,834,871 and 37,821,198 shares outstanding at June 30, 2017 and February 28, 2017, respectively Additional paid-in capital Retained earnings TOTAL STOCKHOLDERS' EQUITY BEFORE TREASURY STOCK AND DEFERRED COMPENSATION COST Less: Treasury stock, 2,737,231 shares at June 30, 2017 and February 28, 2017 TOTAL STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Accounts receivable, allowance for doubtful accounts Patents, accumulated amortization Common stock, par value (in dollars per share) Common stock, authorized Common stock, issued Common stock, outstanding Treasury stock Income Statement [Abstract] NET SALES Cost of goods sold Gross Profit OPERATING EXPENSES Selling, general and administrative Research and development Depreciation and amortization Total Operating Expenses Net Operating Profit/(Loss) Non-Operating Income/(Expense) Gain/(Loss) on currency exchange Interest and other income TOTAL OTHER INCOME/(EXPENSE) PROFIT/(LOSS) BEFORE TAXES Income Tax (Expense)Benefit NET INCOME/(LOSS) NET INCOME/(LOSS) PER SHARE Basic (in dollars per share) Diluted (in dollars per share) WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING Basic (in shares) Diluted (in shares) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net Income (Loss) Adjustments to reconcile net income (loss) to net cash used in operating activities: Amortization of deferred compensation cost Stock based compensation expense Deferred capital gain - building lease Deferred taxes Provision for returns and doubtful accounts Changes in operating assets and liabilities: Increase in accounts receivable Decrease in inventory Decrease/(Increase) in prepaid expense and other assets (Decrease)/Increase in accounts payable Increase/(Decrease) in accrued payroll and related taxes Decrease in accrued expense Increase/(Decrease) in accrued tax liability NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Payments for property and equipment Payments for patents NET CASH USED IN INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Payment for cancelled shares Purchase of treasury stock NET CASH USED IN FINANCING ACTIVITIES NET DECREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD Supplemental Information Cash paid during the periods for: Interest Taxes NON-CASH FINANCING AND INVESTING ACTIVITIES Issuance of common stock as compensation Accounting Policies [Abstract] NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Commitments and Contingencies Disclosure [Abstract] LEGAL PROCEEDINGS Stockholders' Equity Note [Abstract] STOCKHOLDERS' EQUITY Disclosure of Compensation Related Costs, Share-based Payments [Abstract] STOCK-BASED COMPENSATION NATURE OF OPERATIONS FISCAL YEAR END BASIS OF PRESENTATION USE OF ESTIMATES IN THE FINANCIAL STATEMENTS RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS STOCK-BASED COMPENSATION RECLASSIFICATION Schedule of property and equipment Schedule of fair value of the stock options granted Black-Scholes option valuation model Schedule of stock option plan Schedule of information pertaining to options outstanding Number of operating segments Statement [Table] Statement [Line Items] Number of shares issued upon agreement Share price (in dollars per share) Agreement term Amortization of deferred compensation cost Bonus paid to director Monthly payment for agreement Number of shares repurchased Value of shares repurchased Description of payment terms Monthly lease payments Lease payments Officer compensation Property taxes paid Property and equipment, gross Less: accumulated depreciation Useful life Class of Treasury Stock [Table] Equity, Class of Treasury Stock [Line Items] Maximum number of shares repurchased Number of shares repurchased Average share price (in dollars per share) Dividend yield Expected Volatility EX-101.PRE 11 repr-20170630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	4 Months Ended
Document and Entity Information - shares	Jun. 30, 2017	Aug. 04, 2017
Document And Entity Information
Entity Registrant Name	REPRO MED SYSTEMS INC
Entity Central Index Key	0000704440
Document Type	10-Q
Trading Symbol	REPR
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity a Well-known Seasoned Issuer	No
Entity a Voluntary Filer	No
Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		37,834,871
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2017	Feb. 28, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 2,982,508	$ 3,313,265
Certificates of deposit	262,315	262,314
Accounts receivable less allowance for doubtful accounts of $13,046 at June 30, 2017 and $18,046 at February 28, 2017	1,899,622	1,502,030
Inventory	1,267,214	1,353,703
Tax Receivable		172,457
Prepaid expenses	229,667	175,955
TOTAL CURRENT ASSETS	6,641,326	6,779,724
Property and equipment, net	901,464	932,092
Patents, net of accumulated amortization of $188,735 and $180,137 at June 30, 2017 and February 28, 2017, respectively	429,974	426,943
Other assets	31,582	31,490
TOTAL ASSETS	8,004,346	8,170,249
CURRENT LIABILITIES
Deferred capital gain - current	22,481	22,481
Accounts payable	279,130	772,428
Accrued expenses	353,997	417,357
Accrued payroll and related taxes	212,083	177,018
Accrued tax liability	1,384
TOTAL CURRENT LIABILITIES	869,075	1,389,284
Deferred capital gain - long term	15,002	22,496
Deferred tax liability	95,133	82,422
TOTAL LIABILITIES	979,210	1,494,202
STOCKHOLDERS' EQUITY
Common stock, $0.01 par value; 75,000,000 shares authorized, 40,572,102 and 40,558,429 shares issued, 37,834,871 and 37,821,198 shares outstanding at June 30, 2017 and February 28, 2017, respectively	405,721	405,584
Additional paid-in capital	4,117,845	4,129,726
Retained earnings	2,845,774	2,484,941
TOTAL STOCKHOLDERS' EQUITY BEFORE TREASURY STOCK AND DEFERRED COMPENSATION COST	7,369,340	7,020,251
Less: Treasury stock, 2,737,231 shares at June 30, 2017 and February 28, 2017	(344,204)	(344,204)
TOTAL STOCKHOLDERS' EQUITY	7,025,136	6,676,047
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 8,004,346	$ 8,170,249

XML 14 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Jun. 30, 2017	Feb. 28, 2017
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 13,046	$ 18,046
Patents, accumulated amortization	$ 188,735	$ 180,137
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	75,000,000	75,000,000
Common stock, issued	40,572,102	40,558,429
Common stock, outstanding	37,834,871	37,821,198
Treasury stock	2,737,231	2,737,231

XML 15 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	1 Months Ended		3 Months Ended		4 Months Ended
STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	Mar. 31, 2017	Mar. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
NET SALES	$ 1,509,619	$ 1,276,299	$ 3,829,457	$ 2,795,894	$ 5,339,076	$ 4,072,193
Cost of goods sold	536,823	446,618	1,532,158	1,008,749	2,068,981	1,455,367
Gross Profit	972,796	829,681	2,297,299	1,787,145	3,270,095	2,616,826
OPERATING EXPENSES
Selling, general and administrative	637,707	655,043	2,005,336	2,118,159	2,643,043	2,773,202
Research and development	7,872	14,535	24,840	57,403	32,712	71,938
Depreciation and amortization	25,576	23,536	76,781	73,041	102,357	96,577
Total Operating Expenses	671,155	693,114	2,106,957	2,248,603	2,778,112	2,941,717
Net Operating Profit/(Loss)	301,641	136,567	190,342	(461,458)	491,983	(324,891)
Non-Operating Income/(Expense)
Gain/(Loss) on currency exchange	19,988	36,673	34,671	(24,340)	54,659	12,333
Interest and other income	322	321	421	752	743	1,073
TOTAL OTHER INCOME/(EXPENSE)	20,310	36,994	35,092	(23,588)	55,402	13,406
PROFIT/(LOSS) BEFORE TAXES	321,951	173,561	225,434	(485,046)	547,385	(311,485)
Income Tax (Expense)Benefit	(109,590)	(59,231)	(76,962)	164,834	(186,552)	105,603
NET INCOME/(LOSS)	$ 212,361	$ 114,330	$ 148,472	$ (320,212)	$ 360,833	$ (205,882)
NET INCOME/(LOSS) PER SHARE
Basic (in dollars per share)	$ 0.01			$ (0.01)	$ 0.01	$ (0.01)
Diluted (in dollars per share)	$ 0.01			$ (0.01)	$ 0.01	$ (0.01)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING
Basic (in shares)	37,821,198	37,966,501	37,825,209	37,964,985	37,824,189	37,965,370
Diluted (in shares)	37,847,628	37,966,501	37,891,306	37,964,985	37,877,694	37,965,370

XML 16 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	4 Months Ended
STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (Loss)	$ 360,833	$ (205,882)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Amortization of deferred compensation cost		7,000
Stock based compensation expense	7,615	69,714
Depreciation and amortization	102,357	96,577
Deferred capital gain - building lease	(7,493)	(7,493)
Deferred taxes	12,711	(15,144)
Provision for returns and doubtful accounts	(5,000)	(10,312)
Changes in operating assets and liabilities:
Increase in accounts receivable	(392,592)	(376,551)
Decrease in inventory	86,489	1,575
Decrease/(Increase) in prepaid expense and other assets	118,652	(108,855)
(Decrease)/Increase in accounts payable	(493,297)	186,109
Increase/(Decrease) in accrued payroll and related taxes	35,065	(21,489)
Decrease in accrued expense	(63,360)	(67,383)
Increase/(Decrease) in accrued tax liability	1,384	(92,003)
NET CASH USED IN OPERATING ACTIVITIES	(236,636)	(544,137)
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property and equipment	(63,133)	(74,549)
Payments for patents	(11,628)	(29,085)
NET CASH USED IN INVESTING ACTIVITIES	(74,761)	(103,634)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment for cancelled shares	(19,360)
Purchase of treasury stock		(1,105)
NET CASH USED IN FINANCING ACTIVITIES	(19,360)	(1,105)
NET DECREASE IN CASH AND CASH EQUIVALENTS	(330,757)	(648,876)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	3,313,265	4,201,948
CASH AND CASH EQUIVALENTS, END OF PERIOD	2,982,508	3,553,072
Cash paid during the periods for:
Interest
Taxes		90,000
NON-CASH FINANCING AND INVESTING ACTIVITIES
Issuance of common stock as compensation	$ 45,000	$ 24,718

XML 17 R6.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

4 Months Ended

Jun. 30, 2017

Accounting Policies [Abstract]

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NATURE OF OPERATIONS

FISCAL YEAR END

BASIS OF PRESENTATION

USE OF ESTIMATES IN THE FINANCIAL STATEMENTS

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

STOCK-BASED COMPENSATION

RECLASSIFICATION

Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

XML 18 R7.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

4 Months Ended

Jun. 30, 2017

RELATED PARTY TRANSACTIONS

NOTE 2 RELATED PARTY TRANSACTIONS

LEASED AIRCRAFT

BUILDING LEASE

XML 19 R8.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

4 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 3 PROPERTY AND EQUIPMENT

Property and equipment consists of the following at:

	June 30, 2017		February 28, 2017

Land	$	54,030	$	54,030
Building		171,094		171,094
Furniture, office equipment, and leasehold improvements		1,048,818		1,022,942
Manufacturing equipment and tooling		1,031,207		1,003,166
		2,305,149		2,251,232
Less: accumulated depreciation		1,403,685		1,319,140
Property and equipment, net	$	901,464	$	932,092

XML 20 R9.htm IDEA: XBRL DOCUMENT

LEGAL PROCEEDINGS

4 Months Ended

Jun. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

LEGAL PROCEEDINGS

NOTE 4 LEGAL PROCEEDINGS

XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

4 Months Ended

Jun. 30, 2017

Stockholders' Equity Note [Abstract]

STOCKHOLDERS' EQUITY

NOTE 5 STOCKHOLDERS’ EQUITY

XML 22 R11.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

4 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

NOTE 6 STOCK-BASED COMPENSATION

As of June 30, 2017, there were outstanding 1,113,000 options awarded to certain executives, key employees and advisory board members under the Plan.

	June 30,
	2017		2016

Dividend yield		0.00%		0.00%
Expected Volatility		59.00-72.2%		59.00%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		4 - 5 Years		5 Years
Risk-free rate		2.17-2.48%		2.17%

The following table summarizes the status of the Plan:

	Four Months Ended June 30,
	2017				2016
	Shares	Weighted Average Exercise Price			Shares		Weighted Average Exercise Price

Outstanding at March 1	1,345,000	$	0.39			1,060,000	$	0.37
Granted	18,000	$	—			—	$	—
Exercised	—	$	—			—	$	—
Forfeited	250,000	$	0.36			—	$	—
Outstanding at June 30	1,113,000	$	0.39			1,060,000	$	0.37
Options exercisable at June 30,	538,000	$	0.38			—	$	—
Weighted average fair value of options granted during the period	—	$	—			—	$	—
Stock-based compensation expense	—	$	(37,385	)		—	$	50,055

Total stock-based compensation expense, net of estimated forfeitures for stock option awards totaled $(37,385) and $50,055 for the four months ended June 30, 2017 and June 30, 2016, respectively.

The following table presents information pertaining to options outstanding at June 30, 2017:

Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36 - $0.41	1,113,000	5 years	$	0.39	538,000	$	0.38

XML 23 R12.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	4 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
NATURE OF OPERATIONS	NATURE OF OPERATIONS REPRO MED SYSTEMS, INC. (the “Company”, “RMS”, or “we”) designs, manufactures and markets proprietary medical devices primarily for the ambulatory infusion market and emergency medical applications as governed by the United States Food and Drug Administration (the “FDA”) quality and regulatory system and international standards for quality management systems. The Company operates as one segment.
FISCAL YEAR END	FISCAL YEAR END On March 22, 2017, the Board of Directors approved a change in the Company’s fiscal year end from February 28 to December 31. With this fiscal year end change, the Company will report one-time, transitional financial information for the month of March 2017 and the quarter April through June 2017 on Form 10-Q.
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited financial statements as of June 30, 2017, have been prepared in accordance with generally accepted accounting principles and with instructions to SEC regulation S-X for interim financial statements. In the opinion of the Company’s management, the financial statements contain all adjustments consisting of normal recurring accruals necessary to present fairly the Company’s financial position as of June 30, 2017, and the results of operations and cash flow for the four months periods ended June 30, 2017, and 2016. The results of operations for the four months ended June 30, 2017, and 2016 are not necessarily indicative of the results to be expected for the full year. These interim financial statements should be read in conjunction with the financial statements and notes thereto of the Company and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report for the year ended February 28, 2017, as filed with the Securities and Exchange Commission on Form 10-K.
USE OF ESTIMATES IN THE FINANCIAL STATEMENTS	USE OF ESTIMATES IN THE FINANCIAL STATEMENTS The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Important estimates include but are not limited to, asset lives, valuation allowances, inventory, and accruals.
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09—Compensation-Stock Compensation (Topic 718), which provides clarity and reduce both (1) diversity in practice and (2) cost and complexity when applying the guidance in Topic 718, Compensation—Stock Compensation, to a change to the terms or conditions of a share-based payment award. The amendments in this update affect any entity that changes the terms or conditions of a share-based payment award. The amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017. Early adoption is permitted, including adoption in any interim period, for (1) public business entities for reporting periods for which financial statements have not yet been issued and (2) all other entities for reporting periods for which financial statements have not yet been made available for issuance. The amendments in this update should be applied prospectively to an award modified on or after the adoption date. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption. In June 2016, FASB issued ASU No. 2016-13—Financial Instruments – Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments, which amends guidance on reporting credit losses for assets held at amortized cost basis and available for sale debt securities. For assets held at amortized cost basis, Topic 326 eliminates the probable initial recognition threshold in current GAAP and, instead, requires an entity to reflect its current estimate of all expected credit losses. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial assets to present the net amount expected to be collected. For available for sale debt securities, credit losses should be measured in a manner similar to current GAAP, however Topic 326 will require that credit losses be presented as an allowance rather than as a write-down. This ASU affects entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off balance sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in this update are effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is assessing the impact of the adoption of the ASU on its financial statements, disclosure requirements and methods of adoption. In May 2014, the FASB issued ASU No. 2014-09—Revenue from Contracts with Customers. The ASU clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP and International Financial Reporting Standards (“IFRS”) that removes inconsistencies and weaknesses in revenue requirements, provides a more robust framework for addressing revenue issues, improves comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, provides more useful information to users of the financial statements through improved disclosure requirements and simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The amendments in this update are effective for the annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Full or modified retrospective adoption is required and early application is not permitted. On July 9, 2015, the FASB issued ASU No. 2015-14 Revenue from Contracts with Customers (Topic 606); Deferral of the Effective Date, which (a) delays the effective date of ASU 2014-09, Revenue from Contracts with Customers (Topic 606), by one year to annual periods beginning after December 15, 2017 and (b) allows early adoption of the ASU by all entities as of the original effective date for public entities. We currently anticipate adopting the new standard using the modified retrospective method beginning January 1, 2018. In March 2016, the FASB issued ASU No. 2016-08 Revenue from Contracts with Customers (Topic 606); Principal versus Agent Considerations (Reporting Revenue Gross versus Net), which is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations and the effective date is the same as the requirements in ASU 2014-09. In April 2016, the FASB issued ASU No. 2016-10 Revenue from Contracts with Customers (Topic 606); Identifying Performance Obligations and Licensing, which is intended to clarify identifying performance obligations and the licensing implementation guidance, while retaining the related principles for those areas and the effective date is the same as the requirements in ASU 2014-09. In May 2016, FASB issued ASU No. 2016-12—Revenue from Contracts with Customers (Topic 606); Narrow-Scope Improvements and Practical Expedients, which is intended to not change the core principle of the guidance in Topic 606, but rather affect only the narrow aspects of Topic 606 by reducing the potential for diversity in practice at initial application and by reducing the cost and complexity of applying Topic 606 both at transition and on an ongoing basis. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements for Topic 606 (and any other Topic amended by update 2014-09). In December 2016, the FASB issued ASU No. 2016-20 Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers, which represents changes to make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. This update is the final, combined version of Proposed Accounting Standards Updates 2016-240 and 2016-320 (both entitled Technical Corrections and Improvements), which have been deleted. Based upon our initial evaluation, we do not expect the adoption of the standard and related amendments to have a material effect on our financial condition or results of operations. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). The main difference between the current requirement under GAAP and this ASU is the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases. This ASU requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term (other than leases that meet the definition of a short-term lease). The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for initial direct costs. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases). Classification will be based on criteria that are largely similar to those applied in current lease accounting. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. This is effective for annual and interim periods beginning after December 15, 2018 and early adoption is permitted. This ASU must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the potential impact of this ASU on our financial statements, disclosure requirements and methods of adoption. The Company considers the applicability and impact of all recently issued accounting pronouncements. Recent accounting pronouncements not specifically identified in our disclosures are either not applicable to the Company or are not expected to have a material effect on our financial condition or results of operations.
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company maintains a long-term incentive stock benefit plan under which it grants stock options and restricted stock to certain directors and key employees. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model. All options are charged against income at their fair value. The entire compensation expense of the award is recognized over the vesting period. Shares of stock granted are recorded at the fair value of the shares at the grant date, over the vesting period.
RECLASSIFICATION	RECLASSIFICATION Certain reclassifications have been made to conform prior period data to the current presentation. These reclassifications had no effect on reported net income.

XML 24 R13.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

4 Months Ended

Jun. 30, 2017

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

Property and equipment consists of the following at:

	June 30, 2017		February 28, 2017

Land	$	54,030	$	54,030
Building		171,094		171,094
Furniture, office equipment, and leasehold improvements		1,048,818		1,022,942
Manufacturing equipment and tooling		1,031,207		1,003,166
		2,305,149		2,251,232
Less: accumulated depreciation		1,403,685		1,319,140
Property and equipment, net	$	901,464	$	932,092

XML 25 R14.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

4 Months Ended

Jun. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of fair value of the stock options granted Black-Scholes option valuation model

The risk-free interest rate was selected based upon yields of the U.S. Treasury issues with a term equal to the expected life of the option being valued:

	June 30,
	2017		2016

Dividend yield		0.00%		0.00%
Expected Volatility		59.00-72.2%		59.00%
Weighted-average volatility		—		—
Expected dividends		—		—
Expected term (in years)		4 - 5 Years		5 Years
Risk-free rate		2.17-2.48%		2.17%

Schedule of stock option plan

The following table summarizes the status of the Plan:

	Four Months Ended June 30,
	2017				2016
	Shares	Weighted Average Exercise Price			Shares		Weighted Average Exercise Price

Outstanding at March 1	1,345,000	$	0.39			1,060,000	$	0.37
Granted	18,000	$	—			—	$	—
Exercised	—	$	—			—	$	—
Forfeited	250,000	$	0.36			—	$	—
Outstanding at June 30	1,113,000	$	0.39			1,060,000	$	0.37
Options exercisable at June 30,	538,000	$	0.38			—	$	—
Weighted average fair value of options granted during the period	—	$	—			—	$	—
Stock-based compensation expense	—	$	(37,385	)		—	$	50,055

Schedule of information pertaining to options outstanding

The following table presents information pertaining to options outstanding at June 30, 2017:

Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life	Weighted Average Exercise Price		Number Exercisable	Weighted Average Exercise Price

$0.36 - $0.41	1,113,000	5 years	$	0.39	538,000	$	0.38

XML 26 R15.htm IDEA: XBRL DOCUMENT

NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	4 Months Ended
	Jun. 30, 2017 Segment
Accounting Policies [Abstract]
Number of operating segments	1

XML 27 R16.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)					4 Months Ended
	Jun. 24, 2016	Jan. 01, 2016	Oct. 21, 2015	Dec. 20, 2013	Jun. 30, 2017	Jun. 30, 2016
Mr. Andrew I. Sealfon [Member] \| Lease Agreement [Member] \| Aircraft [Member]
Lease payments					$ 5,668	$ 7,167
Mr. Mark Pastreich [Member] \| Lease Agreement [Member] \| Building [Member]
Monthly lease payments					11,042	11,042
Lease payments					44,168	44,168
Property taxes paid					16,236	15,825
Clinical Research & Support Services Consulting Agreement [Member] \| Dr. Mark Baker [Member]
Amortization of deferred compensation cost					$ 0	7,000
Clinical Research & Support Services Consulting Agreement [Member] \| FREEDOM60 Syringe Infusion System [Member] \| Dr. Mark Baker [Member]
Number of shares issued upon agreement				420,000
Share price (in dollars per share)				$ 0.20
Agreement term				3 years
Consulting Agreement [Member] \| Mr. Cyril Narishkin [Member]
Monthly payment for agreement		$ 16,000	$ 16,000
Description of payment terms		Seventy-five percent was to be paid in cash and twenty-five percent was to be paid in shares of common stock.	Half was to be paid in cash and half was to be paid in shares of common stock.
Consulting Agreement [Member] \| Mr. Cyril Narishkin (Consultant) [Member]
Monthly payment for agreement	$ 16,000
Number of shares repurchased					96,542
Value of shares repurchased					$ 43,393
Officer compensation					$ 0	$ 118,000

XML 28 R17.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2017	Feb. 28, 2017
Property and equipment, gross	$ 2,305,149	$ 2,251,232
Less: accumulated depreciation	1,403,685	1,319,140
Property and equipment, net	901,464	932,092
Land [Member]
Property and equipment, gross	54,030	54,030
Building [Member]
Property and equipment, gross	171,094	171,094
Furniture, Office Equipment, and Leasehold Improvements [Member]
Property and equipment, gross	1,048,818	1,022,942
Manufacturing Equipment and Tooling [Member]
Property and equipment, gross	$ 1,031,207	$ 1,003,166

XML 29 R18.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Details Narrative) - Share Repurchase Program [Member] - $ / shares	4 Months Ended
	Jun. 30, 2017	Sep. 30, 2015
Equity, Class of Treasury Stock [Line Items]
Maximum number of shares repurchased		2,000,000
Number of shares repurchased	396,606
Average share price (in dollars per share)	$ 0.45

XML 30 R19.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details) - 2015 Stock Option Plan [Member] - USD ($)	4 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Dividend yield	0.00%	0.00%
Expected Volatility		59.00%
Expected dividends
Expected term (in years)		5 years
Risk-free rate		2.17%
Minimum [Member]
Expected Volatility	59.00%
Expected term (in years)	4 years
Risk-free rate	2.17%
Maximum [Member]
Expected Volatility	72.20%
Expected term (in years)	5 years
Risk-free rate	2.48%

XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 1) - 2015 Stock Option Plan [Member] - USD ($)	4 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning	1,345,000	1,060,000
Granted	18,000
Exercised
Forfeited	250,000
Outstanding at ending	1,113,000	1,060,000
Options exercisable at ending	538,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning	$ 0.39	$ 0.37
Granted
Exercised
Forfeited	0.36
Outstanding at ending	0.39	0.37
Options exercisable at ending	0.38
Weighted average fair value of options granted during the period	$ 0.24	$ 0.00
Stock-based compensation expense	$ (37,385)	$ 50,055

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details 2) - 2015 Stock Option Plan [Member] - $0.36 - $0.41 [Member]	4 Months Ended
	Jun. 30, 2017 $ / shares shares
Number Outstanding \| shares	1,113,000
Weighted Average Remaining Contractual Term	5 years
Weighted Average Exercise Price \| $ / shares	$ 0.39
Number Exercisable \| shares	538,000
Weighted Average Exercise Price \| $ / shares	$ 0.38

XML 33 R22.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)		4 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Oct. 21, 2015	Jun. 30, 2017	Jun. 30, 2016	Feb. 28, 2017	Jun. 29, 2016	Sep. 30, 2015
Common shares par value (in dollars per share)		$ 0.01		$ 0.01
Independent Directors ( Dr. Mark Baker, Mr. Mark Pastreich, Mr. Arthur Radin and Mr. Cyril Narishkin) [Member]
Description of payment terms	Paid quarterly half in cash and half in common stock.
Annually compensation paid per director	$ 25,000
2015 Stock Option Plan [Member]
Number of shares authorized					4,000,000	2,000,000
Number of common shares awarded		18,000
Common shares par value (in dollars per share)						$ 0.01
Weighted average grant date fair value of stock options		$ 0.24	$ 0.00
Allocated stock-based compensation expense		$ (37,385)	$ 50,055
Weighted-average grant-date fair value options granted		4,356	0
Total unrecognized compensation cost		$ 113,821
Weighted-average period (in years)		17 months
Total fair value of shares vested		$ 9,300	$ 0
2015 Stock Option Plan [Member] \| Key Employees [Member]
Number of common shares awarded		1,113,000

EXCEL 34 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 35 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 36 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 38 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 49 151 1 false 21 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://rmsmedicalproducts.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (UNAUDITED) Sheet http://rmsmedicalproducts.com/role/BalanceSheets BALANCE SHEETS (UNAUDITED) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (UNAUDITED) (Parenthetical) Sheet http://rmsmedicalproducts.com/role/BalanceSheetsParenthetical BALANCE SHEETS (UNAUDITED) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS (UNAUDITED) Sheet http://rmsmedicalproducts.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (UNAUDITED) Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://rmsmedicalproducts.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (UNAUDITED) Statements 5 false false R6.htm 00000006 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://rmsmedicalproducts.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 00000007 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://rmsmedicalproducts.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 7 false false R8.htm 00000008 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://rmsmedicalproducts.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 8 false false R9.htm 00000009 - Disclosure - LEGAL PROCEEDINGS Sheet http://rmsmedicalproducts.com/role/LegalProceedings LEGAL PROCEEDINGS Notes 9 false false R10.htm 00000010 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://rmsmedicalproducts.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 10 false false R11.htm 00000011 - Disclosure - STOCK-BASED COMPENSATION Sheet http://rmsmedicalproducts.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 11 false false R12.htm 00000012 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://rmsmedicalproducts.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 12 false false R13.htm 00000013 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://rmsmedicalproducts.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://rmsmedicalproducts.com/role/PropertyAndEquipment 13 false false R14.htm 00000014 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://rmsmedicalproducts.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://rmsmedicalproducts.com/role/Stock-basedCompensation 14 false false R15.htm 00000015 - Disclosure - NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://rmsmedicalproducts.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesDetailsNarrative NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://rmsmedicalproducts.com/role/NatureOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies 15 false false R16.htm 00000016 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://rmsmedicalproducts.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://rmsmedicalproducts.com/role/RelatedPartyTransactions 16 false false R17.htm 00000017 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://rmsmedicalproducts.com/role/PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT (Details) Details http://rmsmedicalproducts.com/role/PropertyAndEquipmentTables 17 false false R18.htm 00000018 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative) Sheet http://rmsmedicalproducts.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY (Details Narrative) Details http://rmsmedicalproducts.com/role/StockholdersEquity 18 false false R19.htm 00000019 - Disclosure - STOCK-BASED COMPENSATION (Details) Sheet http://rmsmedicalproducts.com/role/Stock-basedCompensationDetails STOCK-BASED COMPENSATION (Details) Details http://rmsmedicalproducts.com/role/Stock-basedCompensationTables 19 false false R20.htm 00000020 - Disclosure - STOCK-BASED COMPENSATION (Details 1) Sheet http://rmsmedicalproducts.com/role/Stock-basedCompensationDetails1 STOCK-BASED COMPENSATION (Details 1) Details http://rmsmedicalproducts.com/role/Stock-basedCompensationTables 20 false false R21.htm 00000021 - Disclosure - STOCK-BASED COMPENSATION (Details 2) Sheet http://rmsmedicalproducts.com/role/Stock-basedCompensationDetails2 STOCK-BASED COMPENSATION (Details 2) Details http://rmsmedicalproducts.com/role/Stock-basedCompensationTables 21 false false R22.htm 00000022 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://rmsmedicalproducts.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://rmsmedicalproducts.com/role/Stock-basedCompensationTables 22 false false All Reports Book All Reports repr-20170630.xml repr-20170630.xsd repr-20170630_cal.xml repr-20170630_def.xml repr-20170630_lab.xml repr-20170630_pre.xml true true ZIP 40 0001161697-17-000357-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001161697-17-000357-xbrl.zip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